ࡱ> }~ zbjbj %jjsPl///8$04X011112222GIIIIII$Ȉ vm-22222m612666212G62G6F68~ 1,0 Pw)/ 4rۀ<0^}5B^6NFacilitator Notes Pharmacology in Older Adults Small Group Session Created by Bree Johnston, Anna Chang, and Helen Chen UCSF Division of Geriatrics LEARNING OBJECTIVES Case #1: 1. Recognize medication nonadherence as a possible explanation of lack of therapeutic benefit 2. List common sources of non-adherence 3. Discuss effective methods for exploring nonadherence with a patient 4. Discuss the importance of drug prices as a potential cause of non-adherence, and list strategies for dealing with this issue 5. (Optional: discuss policy issues surrounding drug marketing and pricing, the physicians role, and Medicare Part D) Case #2: 1. List physiologic changes in elders that impact pharmacokinetics of commonly used drugs 2. Use the MDRD to calculate the decline in renal function with aging, and describe its advantages over the Cockroft-Gault equation 3. Use the Cockroft-Gault equation to estimate the decline in renal function with aging and describe advantages and limitations of this tool 4. Recognize symptoms of digoxin toxicity 5. Gain an awareness of the range of costs of medications, appreciating how much cheaper older and generic drugs can be than newer brand name drugs Case #3: 1. Define polypharmacy in the context of appropriate drug prescribing 2. Describe adverse consequences of polypharmacy, including drug-drug interactions, side effects, and a prescribing cascade 3. Discuss the importance of exploring medications as a potential cause of new or unexplained symptoms Online Drug Pricing  HYPERLINK "http://www.drugstore.com" www.drugstore.com  HYPERLINK "http://www.familymeds.com" www.familymeds.com  HYPERLINK "http://www.walgreens.com" www.walgreens.com  HYPERLINK "http://www.costco.com" www.costco.com  HYPERLINK "http://www.pillbot.com" www.pillbot.com Online Drug Interaction Facts  HYPERLINK "http://www.efactsweb.com" www.efactsweb.com Online GFR Calculator  HYPERLINK "http://medcalc3000.com/GRFEstimate.htm" http://medcalc3000.com/GRFEstimate.htm Medicare D  HYPERLINK "http://www.medicare.gov" www.medicare.gov  HYPERLINK "http://www.medicareadvocacy.org" http://www.medicareadvocacy.org Rough Time Outline for 2 hour session: 15 minutes Introduction to session 30 minutes Case 1 30 minutes Case 2 30 minutes Case 3 15 minutes Wrap up and review of learning objectives NOTE TO FACILITATOR: FACILIATOR INSTRUCTIONS There are a few different ways to do this exercise: Have students look up drug prices and compare Medicare Part D plans prior to class, and come in prepared to discuss them. You can break up the group and give assignments to different groups of students, such as: A-H: Look up regimen prices on PDA or another source I-Q: Assign one two Medicare Part D plans in your area R-Z: Assign another Medicare Part D plan in your area Or have an internet connection in the room and do the exercises together, or if you have multiple computer connections, you can do the assignments in small groups and come back together. Students should be instructed to bring a calculator, a pharmacology textbook or a PDA based pharm program such as Epocrates. Case #1 Learning objectives: 1. Recognize medication nonadherence as a possible explanation of lack of therapeutic benefit 2. List common sources of non-adherence 3. Discuss effective methods for exploring nonadherence with a patient 4. Discuss the importance of drug prices as a potential cause of non-adherence, and list strategies for dealing with this issue 5. (Optional: discuss policy issues surrounding drug marketing and pricing, Medicare part D, and related issues). Case #1: Mrs. BJ is an 80 year old woman with CAD, status post non - ST segment elevation myocardial infarction 6 months ago. She also has Type 2 diabetes, hypertension, COPD, osteoarthritis, and hypercholesterolemia. Following her MI, a persantine thallium test showed a fixed perfusion defect inferiorly but no other abnormalities, and she continued on medical management. Two months ago she was found to have severe osteoporosis, and treatment was begun for that. You see her in you continuity clinic, and she says she is doing well. You note that her blood pressure is 160/88, Pulse 80 R 18 and glycosylated hemoglobin level is 9.0%. She is retired, widowed, and lives alone. Her children live far away. She is still at home, but is having more difficulty getting around and paying bills. Somebody comes in to clean her house once a week. Her Current medications are: Fluticasone Inhaled twice daily Albuterol/iprratropium (Combivent) Inhaler four times a day Alendronate 70mg weekly Metformin 500mg PO twice daily Amlodipine 5mg daily Glynase prestabs 6mg PO every morning Celecoxib 200mg po daily Simvastatin 20mg po daily ASA 325mg po daily Metoprolol 100mg twice daily Fosinopril 10 mg po daily Calcium carbonate 500mg po twice daily and Multivitamins one daily You decide to increase her metformin from 500mg PO twice daily BID to 500mg PO three times daily and her amlodipine from 5mg to 10mg QD. Her other medications are continued. Three months later her blood pressure is 166/92, Pulse 78 and glycosylated hemoglobin is 9.2%. She denies any acute health problems but says she is having a harder time walking and getting around, and has given up driving after a scary episode where she ran a red light. She is having more financial troubles because of all the help she is hiring to manage at home. She now has to take taxis to get around, hires a woman to help her 3 times a week, and is having her groceries delivered. Case #1 Questions: 1. What are possible explanations for her lack of response to blood pressure and anti-hypertensive therapies? 2. How would you explore this further? 3. How much would this medication regimen cost? What resources would help you determine the cost of medications? 4. What steps could you take to try to improve her blood pressure and glucose control? CASE #1 ANSWERS AND DISCUSSION 1. What are possible explanations for her lack of response to blood pressure and anti-hypertensive therapies? Students should be able to list: Worsening disease (DM and hypertension) She might have gained weight Dietary indiscretion could increase blood pressure and increase glucose levels She could have secondary hypertension (renal artery stenosis, sleep apnea, pheochromocytoma - try to emphasize that common things are common) Drug nonadherence NSAIDs, including COX-2 inhibitors, can sometimes raise blood pressure How do NSAIDs cause hypertension? Both diastolic and systolic BP are increased by 6-8 mmHg, most often noted in patients who are already hypertensive. NSAIDs inhibit cyclooxygenease, the enzyme which converts arachidonic acid to prostaglandins (PGE). PGE2 inhibits sodium chloride reabsorption in the thick ascending loop of Henle and collecting tubule. As a result, inhibiting prostaglandin synthesis would increase salt and water retention. Prostaglandins also cause vasodilation. Inhibiting prostaglandin synthesis can increase peripheral vasoconstriction. *The above mechanisms probably augment hypertension. However, the exact cause of the increase in BP is not known. 2. Explore barriers to adherence, including: memory problems conscious nonadherence (due to side effects, nonbelief in drugs, other assumptions) costs/lack of prescription coverage inability to get drugs (might be a factor for this woman who has to take the taxi everywhere) poor health literacy or numeracy - not understanding how to take drugs has osteoarthritis and lives alone, could she have difficulty opening the bottle or picking up the pills? It is worthwhile spending some time talking about ways to explore adherence, including taking a nonjudgmental history. Many people have a hard time remembering to take all of their drugs, is this ever a problem for you? Are there things you do to help yourself remember to take your drugs (e.g. putting them next to the toothbrush, in a pill box, etc)? Do you ever have trouble getting or paying for your drugs? Other ways to explore adherence would include having the patient bring in drugs and describe how they take them, looking at refill patterns, setting up a mediset with pharmacy or visiting nurse, doing a home visit. 3. How much would this medication regimen cost? Medication Costs (for one month of medication) Fluticasone Inhaled BID $94/inhaler Albuterol/ipratropium (Combivent) Inhaler QID $74/inhaler Alendronate 70mg weekly $67 Metformin 500mg PO BID $63 Amlodipine 5mg QD $44. Glynase prestabs 6mg PO QAM $40 Celecoxib 200mg po QD $80 Simvastatin 20mg po QD $136 ASA 325mg po QD $5 (not covered by MC-D) Metoprolol 100mg BID $14 Fosinopril 10 mg po QD $60 Calcium carbonate 500mg po BID and Multivitamins QD $10 (not covered by MC-D) TOTAL $687/month $8244/year What resources would help you determine the cost of medications? Epocrates for handheld devices,  HYPERLINK "http://www.drugstore.com" www.drugstore.com, multiple other web sites (see cover sheet) 4. How could you help this woman with a less expensive regimen? Are there cheaper alternatives (yes, many): HCTZ or atenolol rather than amlodipine? With mild osteoarthritis, it is quite possible that acetaminophen and/or glucosamine might be cheaper, safer, and equally effective Glynase prestabs TM are a very expensive alternative to glyburide.generic glipizide or glyburide would be much cheaper (~$10) with no evidence of different outcomes Does she qualify for Medi-Cal or other insurance? Can she get drug samples? (there are some politics here that you may or may not want to explore) Can you get higher dose pills (sometimes the same price) and split them in half? Can she shop at cheaper pharmacies? Other? What about Medicare D? Medicare D: The Basics Total the patients annual costs. In 2006, the break even point for potential Medicare D enrollees is about $775. Patients whose annual costs are less are unlikely to benefit from Medicare D, although they may wish to sign up for a low premium plan to avoid the non-enrollment penalty (1%/month for life, i.e. a delay in enrollment of 24 months would mean that the patient will pay a penalty of 24% over the monthly premium. Calculate the out of pocket costs: On the basic plan, the patient is liable for the first $250 of actual drug costs and then 25% of the next $2000 in actual drug costs for a total out of pocket cost of $750. Coverage gap or donut hole: the patient is liable for the next $2850 in actual (not the co-pays) drug costs or a True Out Of Pocket (TROOP) expense of $3600. TROOP is calculated based on the retail cost of the medications, so patients may benefit from shopping around at discount pharmacies or using plan-based mail order services. Some more expensive Prescription Drug Plans (PDPs) may provide coverage in the donut hole. While co-pays and the 25% coinsurance count towards TROOP, costs that do NOT count towards TROOP include: Premiums. Patients must continue to pay premiums even if they are paying full price for medications. Medications purchased from overseas/Canada Medications purchased outside the plan (therefore, paying for cheaper medications out of pocket while in the gap may not be wise) Costs incurred for non-formulary medications Medications obtained through drug company sponsored prescription assistance plans. Most over the counter meds, benzodiazepines, and barbiturates Catastrophic coverage. Once the patient has reached $3600 in TROOP, Medicare will resume coverage and will pay for 95% of drug costs. On most PDPs, what this translates to is that the patient will resume paying the usual co-payment. In practice, each plan is a little different and it can be very challenging to select a plan. Medicare.gov has a PDP comparison tool which can be helpful to patients/families who are computer literate. In fact, plans that are cheaper up front may result in patients spending a longer time in the donut hole (see comparison chart)  INCLUDEPICTURE "http://www.medicareadvocacy.org/private/UnlinkedPages/PartDChart2006.jpg" \* MERGEFORMATINET  Reprinted with permission Mrs. Js monthly actual drug cost is $672 (not including her OTC meds). Her annual cost for OTC meds is $180. Her current annual drug cost is $8244. Basic Medicare D plan: $250 deductible $32/month average premium No coverage for OTCs No coverage in donut hole: pt is liable for all of drug costs up to maximum of $3600 in TROOP Blue Cross Medicare RX Gold plan: Monthly Premium $34 No Deductible No coverage for OTCs ($15/month) No coverage in donut hole Tiered monthly co-payments for Mrs. BJs meds: 6 tier 1 drugs $10 co-pay x 6 $60 3 tier 2 drugs $3 co-pay x 3 $9 1 tier 3 drugs $60 co-pay x1 $60 $129/ mo, not including premiums AARP Medicare RX plan: Monthly premium: $9.80 mo Deductible: $250 No coverage for OTCs No coverage in donut hole Tiered monthly co-payments for Mrs. BJs meds: 6 tier 1 drugs $5 co-pay x 6 $30 3 tier 2 drugs $28 co-pay x 2 $56 1 tier 3 drug $55 co-pay x 1 $55 $136/mo, not including premiums PlanA: Deductible?B: PremiumsC. Pre-coverage gap co-pays or coinsurance (25% on basic plan)TROOP pre-donut hole: A+CD: Cost in donut holeTime in donut hole (until TROOP = $3600, ie A + C + D) Time in catastrophic coverageE: Post-donut hole costsTotal costs#: A+B+C+D+EPotential annual savingsBasic $250$384 (32 x 12)$500 Time pre-donut hole: 3.34 months$750$28504.24 months (2850/672)4.42 months$148.51$4132.51$3931.49Blue Cross Medicare Rx GoldNone$408Time pre-donut hole: 3.34 months 129 x 3.34: $430.86$430.86$3169.144.71 months (3169.14/672)3.95 months$509.55 (monthly co-pay x 3.95)$4517.55$3546.45AARP Medicare Rx$250$117.60 $136 x 3.34: 420.84$670.84$2929.164.35 months (2929.16/672)4.31 months$586.16$4303.76$3760.24*Costs are only estimates as plans handle months with partial coverage differentlysome plans may elect to finish out the month of coverage even if the beneficiary technically would be in or out of the coverage gap. #Does not include the out of pocket costs for her OTC meds, which are the same under each plan. BOTTOM LINE: WIth any MEdICARE D PLAN SHE SPENDS ABOUT $4000-4500/year on prescription drugs, so she saves $3500-3900. the cheapest plans may not be those with the lowest premiums or no deductibles. How much you want to get into Medicare Part D is up to you. Review the learning objectives of Case #1 with students Case #1 Learning objectives: 1. Recognize medication nonadherence as a possible explanation of lack of therapeutic benefit 2. List common sources of non-adherence 3. Discuss effective methods for exploring nonadherence with a patient 4. Discuss the importance of drug prices as a potential cause of non-adherence, and list strategies for dealing with this issue 5. (Optional: discuss the larger policy issues surrounding pharmaceutical industry drug pricing, extending patents, marketing, and Medicare D). CASE #2 Learning objectives 1. List physiologic changes in elders that impact pharmacokinetics of commonly used drugs 2. Use the MDRD to calculate the decline in renal function with aging, and describe its advantages over the Cockroft-Gault equation 3. Use the Cockroft-Gault equation to estimate the decline in renal function with aging and describe advantages and limitations of this tool 3. Recognize symptoms of digoxin toxicity Case #2 A70-year-old (white) man with coronary artery disease and congestive heart failure comes in for a regular appointment. He has been having gradually increasing nausea, anorexia, fatigue, and inactivity over a few months. He reports no shortness of breath or chest pain. He has been on the same medical regimen for ten years: Digoxin .125 mg PO QD Furosemide 40 mg PO QD Lisinopril 40 mg PO QD Atenolol 50 mg PO QD ASA 325 mg PO QD His weight has declined over the past year from 70kg to 60kg. His creatinine level had been stable over the past ten years at 1.4, but is 1.8 today. His last digoxin level two years ago was normal at 1.0. 10 years ago Today Wt. 70 kg 60 kg Cr 1.4 1.8 BUN 20 32 Alb 4.0 3.8 Today he appears somewhat thin. BP 140/80, HR 60 and regular, remainder of examination is normal. Case 2 Questions What changes in pharmacokinetics can you expect to see with aging? Based on the MDRD equation, what was his estimated glomerular filtration rate 10 years ago and what today? Based on the Cockroft-Gault equation, what was his estimated creatinine clearance 10 years ago and what is it today? Are there any important drug interactions in his regimen? What are possible explanations for his symptoms? How would you adjust his medications? (optional) About how much does he pay for his medications every month? CASE 2 ANSWERS AND DISCUSSION Question A: What changes in pharmacokinetics can you expect to see with aging? Elderly people often experience changes in physiology and body composition over time that result in changes in the pharmacokinetics of specific drugs. Sometimes those changes can result in new problems, even when a patient has been on the same medications for years. Students should be able to list some of the changes with aging that might alter pharmacokinetics. First, they should be able to state that muscle and lean body mass tend to decrease with aging, which results in a smaller volume of distribution (and higher serum levels) of water soluble drugs such as digoxin. Conversely, fat soluble drugs such as diazepam have a larger volume of distribution due to increased relative body fat. The most important consequence of this is that fat soluble drugs have a longer half life in older persons. In addition, renal function tends to decline with aging. This is not universal. On average, about a third of elders have no significant decline in renal function with aging. Equations such as the Cockroft and Gault equation can help guestimate creatinine clearance based on age, weight, and serum creatinine, but are not reliable in individual cases. Changes in hepatic metabolism of drugs are variable. Cytochrome P450 enzyme activity tends to decline with age, although this is extremely complex, and depends on gender, genetics, the specific enzyme involved, etc. Conjugation/glucoronidation tends to be less impacted by aging. Hepatic blood flow is extremely variable and depends in large part of comorbidities. Question B. The MDRD is a pretty complicated equation, though more accurate than Cockroft-Gault (though it is only valid only for adults between ages 18 and 70 and includes a modifier for white vs black race). So it is the best equation to use if you have access to it or a calculator; in the absence of a calculator, the Cockroft-Gault equation is much easier to perform, though less accurate. I use an online version of it (there is a brief and extended version of it online). REF: AS Levey et al. Annals of Internal Medicine 1999; 130: 461-70.  HYPERLINK "http://www.nephron.com/mdrd/default.html" http://www.nephron.com/mdrd/default.html MDRD 10 years ago TODAY (simple version) 55.6/ml/min/1.73m2 32.4/ml/min/1.73m2 (extended version) 54.9/ml/min/1.73m2 39.8/ml/min/1.73m2 Question C: Based on the Cockroft-Gault equation, what was his estimated creatinine clearance 10 years ago and what is it today? 10 years ago: (140 60) x 70 = 55.5 72 x 1.4 Today (140 70) x 60 = 32.4 72 x 1.8 So Cockroft-Gault, easier but probably a little less accurate, MDRD probably more accurate, but only practical with computer/PDA support. LIMITATIONS: Neither equation is accurate in very advanced age, and both are likely to be inaccurate in patients with very low or very high muscle mass. It should be emphasized that if a very accurate Cr Cl is needed, a 24 hour urine sample should be collected. Question D. Are there any important drug interactions in his regimen? Although many patients are able to tolerate this drug regimen, some interactions can occur. First, digoxin and atenolol can interact to produce bradycardia or AV block. Heart rate and/or EKG should be closely following when this combination is used. Lisinopril can raise K+, and lasix can waste K+, so sometimes this combination can be useful in balancing K. Furosemide can cause hypokalemia, which can exacerbate digoxin toxicity. In any patient on furosemide, particularly in the presence of digoxin, electrolytes should be monitored, and consideration should be given to replacement of potassium if serum levels are low or borderline. Furosemide can also induce renal insufficiency if diuresis is overly aggressive. ACE inhibitors can further contribute to renal insufficiency, particularly when the patient is intravascularly depleted or has renal artery stenosis. NSAIDs and ACE inhibitors can interact to affect GFR. NSAIDs act on the AFFERENT arteriole. By inhibiting prostaglandins, which dilate the afferent arteriole, NSAIDs can cause constriction and decreased blood flow through the afferent arteriole and into the glomeruli. ACE inhibitors act on the EFFERENT arteriole. By inhibiting angiotensin 2, which constricts the efferent arteriole, ACE inhibitors can cause dilation and increased blood flow out of the glomeruli through the efferent arteriole. Possible end result of using NSAIDs and ACE inhibitors: afferent arteriole constriction + efferent arteriole dilation ! !glomerular capillary pressure and !GFR. It is a similar mechanism as precipitating acute renal failure when starting ACE inhibitors in patients with reduced renal perfusion (bilateral renal artery stenosis, volume depletion, etc). In summary, although this regimen can be safe, heart rate, rhythm, electrolytes, and renal function should be closely monitored. (If students have epocrates, they can run drug-drug interactions). Question E. What are possible explanations for his symptoms? Hopefully the students will get to digoxin somewhat quickly. Digoxin can have a number of toxicities associated with it, including many GI complaints (anorexia, diarrhea, nausea/vomiting, weakness), CNS complaints (dizziness, headache, visual disturbances, confusion), cardiac problems (palpitations, bradycardia, ventricular ectopy) and miscellaneous (gynecomastia). At higher serum levels, serious adverse effects can occur and include complete AV block, bradycardia, ventricular dysrhythmias, delirium, and hallucinations. Digoxin lowers the heart rate by a combination of direct, indirect, and parasympathetic (vagal nerve) effects: In the AV node, digoxin. . . decreases automaticity increases maximal diastolic resting membrane potential longer effective refractory period slower conduction velocity (increased PR interval). In instances of serious toxicity, Digibind (digoxin immune FAB) can be used (See page 1021 in Katzung). Try not to focus on the pathology of serious dig cardiac toxicity. Question F: How would you adjust his medications? This patient does not necessarily need to be on his digoxin. It could be discontinued or the dose could be halved. Digoxin can often be discontinued safely, depending on the indication. Recent data suggests that digoxin might actually be harmful for women with congestive heart failure, and men do not appear to experience a mortality benefit from digoxin (Rathore S. S., Wang Y., Krumholz H. M.N Engl J Med 2002; 347:1403 2002). For patients with atrial fibrillation who need rate control, clinical considerations will determine whether digoxin, a beta blocker, or another agent is preferred. F. How much does he pay for his medications every month? Digoxin .125QD $8.00/month (epocrates) Furosemide 40 mg QD $3.00/month (epocrates) Lisinopril 40 mg QD $25.00/month (epocrates) Atenolol 50 mg QD $3.00/month (epocrates) ASA 325 mg QD $1.00/month (epocrates) TOTAL $40/month = ~ $500/year This is a fairly inexpensive regimen, since many of these medications are old off patent drugs. However, even an inexpensive regimen like this one adds up to about $500/year, which can be significant for an elderly person on a fixed income. Please review Case 2 learning objectives! 1. List physiologic changes in elders that impact pharmacokinetics of commonly used drugs 2. Use the MDRD to calculate the decline in renal function with aging, and describe its advantages over the Cockroft-Gault equation 3. Use the Cockroft-Gault equation to estimate the decline in renal function with aging and describe advantages and limitations of this tool 3. Recognize symptoms of digoxin toxicity CASE #3 Learning objectives 1. Define polypharmacy in the context of appropriate drug prescribing 2. Describe adverse consequences of polypharmacy, including drug-drug interactions, side effects, and a prescribing cascade 3. Discuss the importance of exploring medications as a potential cause of new or unexplained symptoms Case #3 You are a new intern. Mr. P is an 80 year old who you are just picking up from the finishing resident. He is here for an acute appointment because his wife says that he became confused and started experiencing visual hallucinations two days ago. She denies that he has fever, chest pain, cough, pain, diarrhea, nausea, vomiting, or any other new or obvious symptoms. His vital signs are BP 150/88, P 64, RR 16. His general examination is normal. Neurologic examination is significant for cogwheel rigidity and fluctuating mental status. He is unable to complete a mini-mental state exam because he keeps losing attention. You review his medical record and find the following: 4 months ago He is noted to have complaints of GERD and BP of 160/90. Started on HCTZ 25 mg PO QD and omeprazole 20mg PO QD. 2 months ago Comes in with gout attack on Right MTP BP 140/85 No further heartburn symptoms Piroxicam 20mg QD added 6 weeks ago Gout flare is improved Complaining of more GI distress again BP again up at 160/90 Metoprolol 25mg BID added. Omeprazole increased to 40mg PO QD Referred to GI 4 weeks ago GI endoscopy reveals esophagitis and gastritis Metoclopromide 10mg PO TID added to his regimen. 2 weeks ago GI symptoms better. Exam reveals Parkinsonism Sinemet 25/300 TID added. Medication list today: Piroxicam 20mg po QD Ompeprazole 40mg PO QD Metoclopromide 10mg PO TID HCTZ 25mg PO QD Metoprolol 25mg PO BID Sinemet 25/100 TID Questions 1. Were any medication errors made in this case? 2. Could medications be causing any of his symptoms? Which ones? 3. How could you clean up this mess? CASE 3 ANSWERS AND DISCUSSION The students may have to struggle with this one for awhile. You can do this as a group, or to stimulate discussion, you can ask the students to break up into groups and assign each group to discuss one of the medications and whether it might be contributing to symptoms in this case. Let them work on this for a few minutes, then bring them back together, and have them share if any of this patients symptoms could possibly be caused by any of his medications. After they flounder, you may have to walk them through the case. DRUG POTENTIAL SIDE EFFECTS HCTZ 25mg PO QD Gout, hypokalemia, rash Omeprazole 40mg PO QD Headache, diarrhea Piroxicam 20mg po QD GI upset, peptic ulcer, GI bleed, renal insufficiency, allergic reactions, bronchospasm, can raise BP Metoclopromide 10mg PO TID Parkinsonism, other CNS effects, mental status changes, seizures Metoprolol 25mg PO BID Bradycardia Sinemet 25/100 TID Confusion, mental status changes This is an unfortunate, but not all that uncommon scenario, where one drug leads to another, until there is a cascade of medications and medication side effects. When a patient develops new symptoms, medications should always be suspected. It is possible that most of his problems are due to his medications. HCTZ could have exacerbated gout. Rather than continuing HCTZ and starting piroxicam, HCTZ could have been replaced by a beta blocker or another blood pressure agent. Piroxicam may have contributed to more his dyspepsia and gastritis. Rather than adding metoclopromide for his esophagitis, omeprazole could have been increased or he could have been tried off piroxicam. Rather than beginning sinemet, metoclopromide could have been stopped. His confusion is likely the result of his sinemet. With all the above changes, it is possible that this patient could be weaned down to only metoprolol and omeprazole. Polypharmacy could be defined as: 1. The concomitant use of multiple medications (>5?, >9?) 2. A medical regimen that includes at least one inappropriate or unnecessary medication 3. The use of medications to treat adverse effects of another medication 4. The likelihood of adverse effects from the number of type of medications exceeds the likelihood of benefit Review Case 3 Learning Objectives: 1. Define polypharmacy in the context of appropriate drug prescribing 2. Describe adverse consequences of polypharmacy, including drug-drug interactions, side effects, and a prescribing cascade 3. Discuss the importance of exploring medications as a potential cause of new or unexplained symptoms __________________________________________________________________________     Pharmacology small group facilitator notes -  PAGE 13 Johnston C$  / 0 1 B C D E l m n ̼ϭrar jB*CJU^Jph0JB*CJ^JmHphsH jB*CJU^JphB*CJ^JmHphsHjB*CJU^JphB*OJQJ^JmHphsH B*^Jph>*B*^Jph^J>*^J5B*^JphB*CJOJQJ^JaJphB*CJOJQJ^Jph5CJ\^J/Cx>j$ $a$$ | a$$a$yz  D / M  I  % [ \ s t $a$$a$$`a$$^a$$h^ha$    , - / M N t u v  ŴţŘ~wᏘfw jB*CJU^Jph 0JCJ^J jB*CJU^JphB*CJ^JphB*OJQJ^Jph j,B*CJU^Jph jkB*CJU^JphB*CJ^JmHphsH0JB*CJ^JmHphsHjB*CJU^Jph jB*CJU^Jph#   5 6 7 G H J K x y z \ s wx[d}~FJpq[ !("$$ % %&&''''' *5\^J5^J>*^J 5>*\^J5B*\phCJOJQJ^J^J 5\^J#j5B*CJU^Jph0J5CJ^J#j5B*CJU^Jphj5B*CJU^Jph5B*CJ^Jph6 <wxg[\g67h`h $h^`ha$ & F H & F H1Ii #gh{| %}~ //WvTgJq\ ] ^ !v!!)"*"+"$$$ & F^`$ %6%t%%%%%&=&l&&&&&'*'+'''6(b(()))K*** & F^''''''''*+ +,,{--a1x13334 4 4 444v556677,9-999|:}:;=<><=g=n=}==?????}@8Aȼĸװ׶כ5CJ\^J^J>*^J 5>*\^J5;\^JaJ CJ\aJ CJ\aJ >*\^J\>*\j\5U\5\j5U\ 56\^J\^J0J5\^Jj5U\^Jj5U\^J 5\^J4******+,{-//!000#1a1K2L233 4)4*444445 & F  & F  & F 55u5v555555'6L6n6666667747d777777 & F & F^ & F  & F  & F 77 88X8o8s88888889,9-94999>9H9M9b9n9s9y99999(Ff$If99999999 :::$:0:>:C:J:R:j:s:|:}::::::::FfFfF$If::::;;;=<><==D=E=}===$>l>>?????~@ A8A9A$a$FfΕ$If8A9AAACCDDFFFGMpMM9O:OpOqOrOOOOOPPPPPQQ-Q.QRV["]^.`ajceeeeffɸɦӗӗӗɂ{ӗxt>*^J^J *5\^J *5B*\^Jph5B*^Jph 5>*\^J0J5\^J"j5B*U\^Jphj5B*U\^Jph55B*\^Jph 5\^J5>*B*\^Jph>*B*^Jph>*B*\^Jph B*^Jph-9AAABBBBBBBBCCCCCDD DDDDDFEEE'FNFF$ & Fa$$a$FFFGHH2J3JKKMMN8O9OOOOOO;Phhhh'k(k`kakkkl'l ^` 0^`0$a$f[g\gdgxg>hhhhnnnxnoo9osqrx#x&x;xyiyyyyyyyyyyyyyyyzzzʿ0JmHnHu0J j0JU jU 5\^J ^JmHsH 5>*\^J>*^J5CJ\^J B*^Jph^J''lEl]llllll mHm~mmmmmmnn3nCnZnmnnnxnnnoop^p ^`o9oOqPqsqqqBrrrrr-vvvw\wwxx;xxyiyjyyyy`  ^` yyyyyyyyyzzzz$a$ # 01F/ =!"#$%DyK www.drugstore.comyK 4http://www.drugstore.com/DyK www.familymeds.comyK 6http://www.familymeds.com/DyK www.walgreens.comyK 4http://www.walgreens.com/DyK www.costco.comyK .http://www.costco.com/DyK www.pillbot.comyK 0http://www.pillbot.com/DyK www.efactsweb.comyK 4http://www.efactsweb.com/DyK 'http://medcalc3000.com/GRFEstimate.htmyK Nhttp://medcalc3000.com/GRFEstimate.htmDyK www.medicare.govyK 2http://www.medicare.gov/DyK  http://www.medicareadvocacy.orgyK Bhttp://www.medicareadvocacy.org/DyK www.drugstore.comyK 4http://www.drugstore.com/Ddb  S >APartDChart2006R;ò=s]d̅Fą;ò=s]dJFIFHH:Photoshop 3.08BIMHH8BIM8BIM' 8BIMH/fflff/ff2Z5-8BIM8BIMPHUT5DPHUT48BIM'File written by Adobe Photoshop 4.0Adobed@i=       WX&x9$%ՖhY!1a#'8A"456v7(Qw:2SdtIyRbCEFfGgH) !1A"Qa2#qS$VBR3s6v48b ђCd%5 ?@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@@4@4zzkyfanIxfڿhwJ0ƂI"isɷNb<)yc&O`Yrgsd6lH罌jX%^meqF.>Q:3FOMbYK<:wAY#ƍD#襊NFxK Hݳ$ı/=2~f9][/<| 6JRYG]h%$RHxDc]_M*V? IV{M׈5aU8Tf'7'.~l{[?/g[3~,koS }Tl,v+ A,y%\@Ē_6V6%n_S'ox7ӿ;K4RXevZ϶VVW_е1ύ9Q%gvV{#JDƮUz\*kUZe{H}H$jᨤt9xpa Xi*x(ĝ噹sn֯6DVq _O+mݤu7zXжGBKGV9XsTq=-kSӜ3↉vmجČS|fYMM/a3F7Hf$*Usߦ!xp> _s؎ !gUU=7ȍǘ-3S Wz:N'\v\m|a?_"R6&skI aͤK/r8i%ZE/nmX7)p_x+mPze)9d*7t̃rA@ttd7".Nrc\}2d+qO}ysq6Wjvq:[ĊaI0Vϝ"Y$Q{!L[jDª:+߄ gV.Ƨ;'R; D9f#4gr$u1 ӠB:q~j×ݷ-_/ۿn;2ժ5LlW ȯUr.bd"7 S|>_;-CG';W E ̅+(JHGVF$,˟Svy&³..K~_<vr;W)׊dtublRGB ].UZb5bq=-kSӜ309'.oO,Ḓk9Q=ܯܙ2z}D~^+F&bL$;)kyycgYZ\6J9'ί}ygl7#wMOBVxܭV%FtHMiYlʨ}y$,dGpTcUˏ=Q|3D7'.~l{Y_^(~mYKj=1E_ݏP>U=7ȍǘ-3S Wz:N'\v\m|a?_"R6&skI aͤK/r8i2VӢ6aи\¯< E϶=}ikє2LqPA9 h ::Bfvg'R^91wB>2\xfϾ<9+n;e8-gbE|0$e+jdmgΑ,|Ȩj=Wd r5"aUWW}ɷ4Nwml3f(&1ܤ Z)݁y k.lœÃ/V9uT5ylaՑK1jz9]}[qfKðv=\EWOE?7KRF&1<45 EQ1& 7C0&b\o~wv\ 4JIM>$b%tF=~r~-vڮ䲶r9;L*|> ON:M5pT#CbaĞ10y ~\82:aVɗ"Q$EcSB?Z+T&ݯr=scc v|C[e񔐬oxt1q5 Zl<~&=f7X\sN.ϒ<9ūIol> rSį5kU,Gw_*,ot ּ-{_WDL×& y>%Z-@-,Q87|F! |yIS;?)&ipx1ᗜύ~.?lPݶX&N~JV&_dvZUª)ҳ%Ybdn3n:/ȾH5u@&aRx JumH #ebj*nكIy%' c9҇}pyK÷b tٰ6Ϯs59\dcMZZuV1^TO\aU?Z {6U=_d?ޭSt/F zvfMY:֮^+WRc .l*~'0dHݒqit}j:oƱsז y_ ||>_~K/{`ܻ}Ւ6Hd6O蟥J*IԛrRz3E*韆SU R4)_loe "f)0 Bi~ɗ4YSO.9s=}5{q]g׼mlEC2 IڬVEW#ZeoUvȯVTEL*|\z 7Q ,/T -Jl%๦8X%Ys'hT5?q gtvŕ3{VDYv͖D]>N/?0glp&}9{#c] #YQ3)yҿ2WU8¯ï!}2~wʿ}絲̟^3bqgշ37oͲ\td$fi[pw2tP|l\K; Udݗ 3(Jl cL+仿g!ɸRRܳwe Mbr2ȊƵծrQHcbCF-F&?Ie3WztbT-H=SEj|͈gy,XJG"G,NɧE{bн|jG>.r+k,߆JT& $lى$P$Pbҙ6jVaW6B}δG9,*#1Nr/PQld>#{a<ĤƎr)f4T¼yxcx~R[/;{e2d-wltbe9[Ge\*RN*#q#q~.E_qӾN awxN0:B"lHSeV91+ʅ>͉d?,Q;_f8kO^}HUVFSy]"3JVM(sJ>IFFL.#nMMoO.OѓS7'.~l{SO/{8շ37oe6Y-೺"Tۏ1G c/7%Rz7瓼2v][Y+51ŗ6۾¼k{bm}jI:Mg]Ԯd(+TU\?u7*܂%{&ps9=Q*k?Awe_O/{87gBn7Eb;xqLlf7E93wbs6ݥ1VdO&.\N\p/%xyo5޸' Vmޏg{^XfIO\2VF9DrSډHݜg誟TO-hhl쨁4_0w}&ǘ@@Pid3?4ʹR,jG~|i\fO]Yb*{^kZֱ{WѫU/V'؉}~^~' a'Zc.@jFɊjJ L57&Y|]`'VhgtN Rt/EW㜛;|[35݂$Y,rWsazLWt_3TU}+EUDE뎊d?7l.GlGT8inlު2`zR) dęei^H`P{,l{e_kinsC XV4Ww"y;%&XX^j|Pglj6F别?N\d;tG p-tJvZK& p2Y$IGaWt_0m=7X+σvNuO.7{o>}󝃷wGsP5y9QwSaWrvr}LU6D~جic%_){/~㩢)71J ufY$09VHșPL#9 ܺS"'F<dNeCe:9Žd:u7qas%G jtHdkEFm[vcr)0S>^ؖ@4@4XXM~dӆA Jb5SFawj1AW)YR0 jWNѰyǛϭѴnsmK*e2++#cs>H3ѽĒ؛X.r+W)Q}QrK_\i=w  QH&U^.5I92 +A^|qя4avmkŅc4#t~6柆|k%+-;X ̉?fh l5;['E_g7n7#cQrʭTrԨz}T\ډ'Ю?W")J\vWC[xtu$ '98wG)EYإK\)Rlv}^Q=>Z'tTieA]]U9̆udL1#6F܅wjXG-hpDDUU_U2Qr:uGCNF:BCU֢ p kD+9qAs?fG8pɿ,/OR[Uټm[uԒ=wR%tqk$֨Giejo(ƕEUzeSׯ"㧍Gw9|wDRy1_sN,\S/rzaaHrļ*-q8 yl֧d[t|gK.ޢ5̢9m5ʑ4tEsYPfcwˑb".UyF_r~{m8gi94L>?{wnI}8k=ym~N:|?@䉹ٟZ;ҿV~5u+;:IrΊq5t?OF߉*ArY_)m|vNlK,$`dgb -rZNФYJ9a۽~9 կ;K,l ꭑd3$gݑN97+]+U9kCr""꩔Tҋק۪:Zv1·2G }K|X>O J$iYˌdfm28ÆMgt~x5ߒ׮܃jۯ{‘+\Q$tpG:;M-U{}D4.z_*~ؚ{= !Y 8,oUccRYu3N+sK )z h|⑟3mZ6zIX񏅹/o"0rO.퍺)[ HWb-h76+\͊ƖMu]a!F$zWW?2.sSdnkч=j,>AF^jj;009Svԧhv{#Cq숻Wc>yü\}llSG~)Բ_yyjУy$6{_ׂ70\3ƛ{ehΛo"K>һFtWn{Rhs4?'g~\}^KĆh4cӌ}ӵ~B_t߶6 4.enN1c MI*C\%%sf uū7xfw nm;˸#VԞE֗NuՊ1^]UDؓnH3(#> "eꇉISЛLܿSk~lgz;؉0{S$X'Z\7?{wnI}8k=ym~N:|w$M͵ nݟxNjYהFc)詧_OO_c=O߷|*߉O[4wn>"=~Z}{]g\ 6i ?d}MfŎwo!{\?A]=lK$Uտ?GwaU?*Mq5z_՟LuˮqODUTa!n[Bc5rzY06Ɂݳ'9Nƻ06r~a}G~g9`}dt}۷`J :.F\-Xv.+3-\ׯT?Vek*?t7&S#$Gl#an[>O8M̜ॴ(nA 󏍹$orͫr}{+$|jժPԞxX(bcە-]iݔD\=W#UW9꿦Mė7?BlM=EBA)oC!cR0b-. B6!13tai mٚw^r,d$xSyC7z[c+$|Գ_d-{Y/n>ֶV vɩWkIU^~+0 _.aN].dV[\xt\c&1`.h*3}6Q-ruj gd@ɕb^{uƅʢ1ޯOYNsqv#{Κ66Z|{Z_86tb7\H_D[E1=/^\+'\e4,JȒ,ɑן5yb7=9.kYWs\'x˓G4fD$hH|1(RBnD굝QQ2ak_;]QF#N:wX3-7v +$jbgvIC̖ ?)bmƷ7&C3loO(~E}|ƖZJTK+ṉ=eFic1bv)V7s]ZW"*c ժn} 9/?3BR.,}q832CeG*uǢ/t;ff0ĥM^,S# |ta&1YYf$Mݝܻ~L)fǖn<;OUɾXH'Qswdq#Z(V'#cϙ%B*DEgLyTLUs"eW>[ ծH CrhlDbl /\k2Y%Dnt2/+ܹ7,Z}cۼ{|k h߳{nG~*D0#eΕYY8Hekڹ#;M*֦1.U> Urem_WQ}bajwDY:%8N<mߝ_ՌKdxS^}Oo](~mO~avZ>~:4|ڱ chs볟LhfshO 侮;ž?{sZ?*yae%7|w_wxgԗ7ϧrm?kX[L/ybۻ:acnݟq4_ugM$+k]h*1@a_z;s,17^.[{[l }!BvK[g&Os^I3aUSEZu-ٶm)+E_DyOE Zxtz}NCHX;\~.G  {yQƈ2? g/X^9"r&2ΉG Y3u_& mv4},_Vv^K$8fastwR/dˆQ1*S:A]u${$?tŹծ,ApL,hd́fʣxChkͼ?MC٨ZZG2J~#o6>r? er"9ۭ ;bJ9szts؝:'U>iRA ]/,"wrNCN"=6- ;3 H&rg|F*< v͏w?8^;3lh֎;uhnZFTltm|K,FEt{_$vt{8sTªtT-pzQM]g w.6ٚ"#D,#-:^,Z:lܷ£OqĻ7џyݸ÷Ls$m+$r%Б6vw\ٮ56BhoonUޚtǔ.|?I%zD]]⮉Q;KY^IGč> l 應};ؽ{{?}]m7 ~Hms{n޻>vׄ^[{FIޝ)|| 省s{ަ %D/OgzD|oz.5S<]?{_u[ϖ}4;=Οʹ}t\hʛtn^KN:0?~?;ݽRQ Ѩy ߏu} !nz[~2_N5En蔻'u?)'<Á"-AZk_]cʑ }G9m69h%ټK<5Vq-+*luG#czLؑQ=t2ee;m҉ӏ1 c;A&UJ 4L9&ݠ9 H0 rCru!CTbwǎ۹~xöN87yۮqk+L#4l.R]oG0ˑ޹u+"|oljŎ*a:N0umUPW@fצImuc<- RZAXAl`1Sd 1|M_O|>U>ߙyEm_2r2dUEnæIN 77ZhݾUDSgҘO'^HO/]7<>O}m>sw'eG;/~忞K¿{ݟk9{{~?a_vK;=}f>MX}w&U/JG> ݭ#GtW9r:"&37sV zϝNJsՊaw X#\,ґp F4OAMeV>,lvɇd𛿘9.^/Thm7nXRӤ{[#gDpcR=͸5H*M8}ʟu?ubwm30tO s[=0*oݼ_v[dǛ? kWμy¼gl{blIdEX79sdQUj5[m79Tesz{NU֚ye[%)sp5'T7Zi{&F-{̽&UO ێ|rt~e QֶHXҜmVT%"fFUF鶪`OER(rF᪢UZWH#zOʷ}) L8 uauxZ{$ˊՓ}l?XKןs[ߑriag5ZceI.aY>R]ժtՌ+r+D'RN"uM.Ze2_McvU0$ HQq<:54.GԦU<>_7-e6lȏϳ=,$OW*̝5\L"7}OЙ?ubwm30tO s[=0*oݼ_v[dǛ? m|׏8W=mlM t H5ӺKF9s?ʭFt+[qz.sL&W=0WT]iIU^-1G RuCx놚Dzdo"׼eT>7ɇ*MCwH~#v/P6]uC$Xt=k jmGHD{^"Sg=mIGXµYʮpNvL-=@$ekNc" >`7b1*y,A?iNld)UV4(2T8W$NҺ)#{Vl1fiU6jX8UƤUUvQqNL:*m{3w؞A&6B홻%,ehS;[A@\je bE4 < n[>gZ9'W* IߎWڊ$|kL6\D6!!j1w#TcتeYz[ ƈҭs~(G.:>sOӥ/y#uvmA,MUjr^ ?*Ρ$F0'%Յ׺i֯p.*;VM˶ `y/^}l{~G} Wk۩U$fKv sVUۇV0\~\zaJ]:gԉ4Yi1~59Tsdd4n"G PxлqRV~*۔shdc>tFX9>TDz5^Ƕ2tr0^ީ>BkJV%;vHvucc,~m 4hQv=|yD;joLLka6ObMFAFjuje6.ء R&1BcLI\๬}Pv73?,}-L:!FUJwu jͿGȔ8ѺynvLloxdldx>Øs?g'nLi誽r^mVqO'8q<:$ۺ/-P.ؽ߾Q}C73A0 Ƕksw9|gibøCR\NW-T)X$:yejT|-Fj7m ݕ,ˑTr _\|2-EeWG`%_%ʹU5 YQYfiܯWNUGtQmкb]**Qӡtn]ZSV ;o(H?X~$0;fAػ/c~??u!?8 GʙŶݶi7xcWd|m%ea5\*^cNWl{#UTҩ8/|MԳ: Z V(m\b0{yf_gEMOO:8V:KhܭRs;?Hu2 x#a GU2|9 ?q;^[*ɿ*KaET\J~<6 ů'5,~fqȑ9Z>m m=eXѝU1Q'_3>t-JjH3aTO biAer*" h HvKacF2(y,L}BsN㍋ܳnm]5ϛvWDMp9=keOnKr~rޚzӔ0wBLH5`;YI=WX h}O =-*p3Z4TS:=lyQ`7yGѢ1^e{%[MloI34:LMY6d;te4Lg?2~Ko8d:^m~þG}sSqW;SEO k[ozoCj⯵xe|5S3R2s#0ppCD_&ҖV"f`§>Hpˆg>LXi6}˷ڍcI$d5nU|ʬ=ʮYtх 39^U\"*޸a>B *Oz΂ IP<>&b!|c8ٲ%ˑCW쮲yr[?$qハ>92d>W6{}϶[I0Zہl TEbRUʊ[Wq$j7TD*ūש'·~XrY >aÅ$65=V!/#^;-[@*7q;HZ XWX"J2!}doȼ[s46ˬXu8gdD%|#X kVQh*N YSR~ލNh9:d:^m~702v{%߭%9QhG҇%{dx'P5#Z{r8io?z`|l{??أڬvᴚ+ê̿O?ϒ,F_ܹ`,^V|IK/Z+ u-wAU*JF@dơ$7(:T Vq}J3zMaW#t5Er\)ݳ%e$v3n:"'Ū9Qw!K tX6P"A'HZ$\-uoL!Л&Ux'ݱB{`&)w+;mq<Ϸ 2 HvdEVvFlkZcGɘečҽ[驮2t/à J@*&a2MIF#`kZZ+jdőfTȑȣ>Xb(9g%\q&nlh䍲X=#Tb9r7rYblUj53L&~&=5`Ǩ鄮YW=X6w}Q25) 0o3D4&UoBlvO`ωxQ1}ec%KNlY7e6; \;U{|1ߛpkޑU2q&3>?hjrwQ\z38"!t{kZU)aZfiߖ<Чۚt{ly%Fym6F:&lHҋ(:O2)6d;te4Lg?2~#tՂ0Se$]bgp$E=RrL>\ 4Ls(č`F+#S,Cea7n=gqrZҍkǿR^FոlP e[b$%FO=ȓ&k[#շԶJ,]9n1詌t65|ȯľ2 ^x]sn|=ݾ#'?\wv~v1i>ONm~_{/ayk?}ӡnTdC_{8{Lp)%C"8c?! fjsXa;^T \Rgo?~[mڸǹ}*:6'{WIa,32ܳ=s)*ҕgjcUN?ttZЄ @4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@@4@4@4@TQVC,\Or듳 QT4K{MXH[Z>aktTX(N\{s2sp+N k zXqݭYOJ),%3/Ɂ $x'rVw,xؔwN7Bj>Ytc-zX@ϩP+}u7gtXG3q^Zq*P>,@Jb~kdrBqoLg9=,CC`Ɯ FB33{W *SˊdrJ޹&.(P-Q^ ΝUjh$5&X_ᒠ?|@|GF}VۻLYzk{q{yOs/ ?=0me<ʿxߗ׏ǽ{=ڻ?>m DL`+ehH>44)w7 G?'a,)@" ܾ2p+aَ?#)b%Ė1o$(W>Fc N@BȚ(qĥ:tgZ> \G('ou]GZA@!A <5^?)xBtiu^2?d Q :ݱA>UuKؠc:lPOwhG('ou]GZQ :([vWր~}-b}@? >ݱA>UuKؠc:lPOwhG('ou]GZQ :([vWր~}-b}@? >ݱA>UuKؠc:lPOwhG('ou]GZQ :([vWր~}-b}@? >ݱA>UuKؠc:lPOwhG('ou]GZQ :([vWրUF@ЌE:RNeal8NQד.ebhV@\ra"dX1r 84@@4@4@4@@Oڛ[?P ~hzs}c,eO:v[ vwR&o(N^B>a(rhƶ"Ɯ(k+c;to .PmDi,edh4YՠZ[8 DgJ&4N>bE#}fU̝Rp.}4L>9H9&V:g!">Ms GAG%̡\rt/oMKXb~]:1fD1" EMe&r[YgdbLW7ǎsu~/z`9b4_I^d˿EO=}k>7gxtRuzXzŵlWPbv!N0Ox oD Bw "Cah,<=O75k`Vβ*iفD>(aDL\%r)Q|\ wc˔2W5i"bʜ>ہ I"L;il{X| d11йk[vD.v#G UEN g1!7*S"LEPkkQ\|py#%tߓ1K%D?,ېdL[6ݨPez^_?sPW<<šMTD2fr6L6|@ВÝѪnPN;cz[I-8~<[_NIPpn%Íq4rv$+~GF\Z;("x3j $uR./ cDu\@4@4@4@4@@Oڛ[?P ~h Rt"6D 8.~W'G"z=PfQo!*DQϒ&rw-i2;=D"fRmA~uHF_>`Ma"H ^lG佬7dnoʥ)b逈d]\;``D)a&O|K G`dPB+7.3_9HYi<7)PcL*X$CdȭK љG/e㭛1d#IC+Hk`]֙6c[Z@ j+/D3j~2{qn Ś3+d^ApzJQ4+.: 0[Ȇ+$D:):Л~$4mJ%r*%hqRWRXxeR]zwc|.6!o?5ܣ]\e+`u&DcP!%g?<,(wqInR8y6p7{t:mlހNf}tRg&nji*0ʸT_ĜAn'*@<6 0Yŕ[‘|hiIcxIs_c 8E,ƳL^x_#^xe)q`surT0{c6,y8`:x~OkWPΘyX/xJooM<嘖=s`Dee*1@`2[I93m+xu;ŬDeir^qpf&%d3l/jeQG~+1^%R( C9xVZq>ǒG?਴*n/)|ÒֿHL4+ă`p\< ٞH#/7- j낎q%rYy-4UWW<>/yN$yQ Tض$Kf(DAGu! J:Ju>f2U4w 21cU)w 9##♴Y J2O’e%gj11]h9l&Ra$aT|:ŮuSG,}::cD^2ջȐr$ ~mŜ (rFp$3p=-DfĢ }r:\` i 6V[ N'sŜGHmn=0 J2B$K~4@4>< Ů&0m3XT!.r *p>K܊ӵL#,P7s$TS 2da#Z5n^.Dlb\k̜.YFU!9i*lfXeׁam-N ")4$@2h!t|  +qVl;㈀@4@4@@H\_깠'ހh@4@4@4@@Oڛ[?P ~h AET4gtB~W4vrW;IʳA39 Jc Zڌ+K0YxuO@߻xWeg^/}o{]fR``Ԁ9BP%e"a.7OK<šrYA9(O(·!Z󍫆8t" -[ xQoP ~/l%X1I~yQ93 JGR`@aIT 9G0)q9GYże߰3)L#CS4x0Kd+Iէ[Gr8s>/0}:.(黇-1T^tld]gX%#eL1J5433),o[(2&Lrk3/svapj8K? vLc\ Pn4xa  )0^j4rfhdJ1uOkagL(HB榝ߘcC#~F V]jG<0N׋|Qػzh@U,+vHe, "V覡Oe G'O\`3Lgye%bwV$d8}k-scB\#& ULF^:H9E++ [p\*''.XHHbuBSd 3dndC#C@n-1Ov>fe5bm}ĬLZ cU;;@$=R$s+~5~ ?+|[l?ZblGVk&o/;j n /&?G(w5h{ !]wf{qG|E ? `xC޼Oy?Oӭ.ɱU`9[ cv)Z^zvWWIz\er%jmD[8ELj/dXP?!Wn,nv`vv=سprc`211`1a`aa06faAaCC鑴014•4q'J xqǏ0$ϝ.:?gr ;q3*&kDv QpG/ w]\2e!8beA׽# C 3> PB +:b(LrxL-=|g&ﳠ"k06) W/x"dr?*^F_1cGƸy#+5;Zjȁ8I@SJىYx(>QdF̥$,ES7Eµǘ>I xr7H0Sf./ZɤQH@Un]ڀ$w7?i㺑96`b*Ie[E/d;uqeg8l; "`zP/,MfbE8T1:Wz)U +ԒR)`~ Q n9 ; $uR./ cDu\@4@4@4@4@Eޝ8E0CAf `4[ءĕ=eU+Eq(nœ ~zT.~Ω|]6+-R>lW[:}tخHuH]o\b"߿޹#wEsG@? ~zT.~Ω|]6+-R>lW[:}tخHuH]o\b"߿޹#wEsG@? ~zT.~Ω|]6+-R>lW[:}tخHuH]o\b"߿޹#wEsG@? ~zT.~Ω|]6+-R>lW[:}tخHuH]o\b"߿޹#wEsG@? ~zT.~Ω|]6+-R>lW[:}tخHuH]o\b"߿޹#wEsG@? ~zT.~Ω|]6+-R>lW[:}tخHuH]o\b"߿޹#wEsG@? ~zT.~Ω|]Z 6. "3MV\^.p]FY fWxvHaDٙnj]ß>[r @4@4@4@4@4@4@4@4@4@4@4@POO_ۡ$m @4@4@4@4@4@4@c壟Ĥ㽻.yni흛ԧc'˷[Q5ߤy%<tx(;kſI@!^-Jy(oPwG@<׋~?C:,,AIb063ǐ!bb&,D V4>̕b5XrT/ؾL0\?ǃj9\T|o?֍8rG};x:o_\r-/YpE~~Ԯ=.\&."CViL6&!܎7捓Uҥ׀ouk[=J})qAގ,axlv2ܜř#MܲAcTŬNM.P#Ff`ɑBT )t6%H=H*2 yC̮Cʍ ^dwxzøpLR7SRcDGZKgH0Se 1J3=4x @nQuPebsUf<?'S*0YVr ]ʧU]otJ O ͵nq(CZ.l׽PbL([P]g&!҈tv,Ls,.|U.ɵ:&N Z8V:ALK 4Vɼ1 bg{acS$n["WeyoH}Hjٮ!/QJCj9Hi9q!RrqhU+խc(D5bJ1N +$&U嫾[գ 9 .yM*B$,v2ƤTȿ%lȈ+n5L)K)]rTDۃ|؀^}>C ?wi~a{rP~@%Xp@x}Pm8krfO~"r+Àq ;0;wKJ*{:bly91B>5 }Hjٮ/\3/@hABhEi46:6AӃk}t87" Rr(H"\rbˏxۗm>ñTZz\TȏF)Mds6f͠QR ^lIC,-1jD諹չi,fBtV*"Q8,4rZɑ-CęeguF8kFA <ۇ&nϜ!q#M7l$DNNvw`gHBR1a$%fTi Y0)i"?&ha i EUfw2vlM^Deso xd"QUɩx:RLp= SPhRW>4#=$-)S6qV:5I FϭA/ {Ǒfԁ.#8b}2CַV\нe"yArEAñ~2?9" ?O5`!yuҙd2 Q.{ξs [HJh Td2M^N&b=9Bxb*#'!ZBs>ϓ{%7h)؆Ӹloh@6; Qy,=;q*&piAnũI#fجht+[TYE84{onHD4 e(sp-}aZP Sr`3 izHʩ,\)YHz6ւD՞D#/+wLVe,4j貝6)lx"tElaX6N$rKP S;,A>d_G iL\WR/~=7M {dk{!$&c2Qv:3'foNT\_/ Jl Ʀ썇g{Xx%%²O8 b ~ed׼ް;‘a+`7=4tXꂱ(^9$ z]ZB\Z%!4Wq60,0ӽQP;D3eA?@=QP;D3eA?@=QP;D3eA?@=QP;D3eA?@=QP;D3eA?@=QP;D3eA?@=QP;D3eA?@kzE0Q/QR4t~\;-}U:uDoR]eȧ=s› o @4:2[Vޠ-sgR|MyԨ6'bKK#~ tR|1eP"$ut/n$Mk"elTq)FfE<|M¿,ӵ/mv˗0!$MPzaOLRFQJYn]."x:2(cY&\ur;-JBՍB<= :OY8!@E@q9$6@83(U/p>ҍx6e;:50E 0:ī %ӔQAE3ݬNߢ򹣃YYfGNKI|vrN2Wu @:VY|bDlDNu@Qkr/IPCc$B6?;4`gv̕*O ys^6 #M`1D#H G>'nY!fB,sΈN45;n=qVW )bo}:Pϳ$)8AXcQ $h#1l fGFB0leiF 5md*eiD r!ӱ!<=q(,Ay벌B2L>ŋ>CжqTjD$HO=4r$Y/FÅVBo|rA"$V/3;PꖶՄ懕Gi;Jyەc4&J~9e, VIS$r<5jfԦʔ&!ELf;a3d:/rfߖu N>.m \=obJV1`hJX@\x(mlk;58pqZhh l?fdX`7yBHG/[gwd]ꔑSmSMY0H͇d(H }uXHBXjY92DNO>Ʃh+gB:ȐOm=Y:|vh+^E_Nʼn L&T0l {nwV9Ɏo_`sbN?B7>˖uz)=-sE[8c*h~F`fRYYK:O,_Z8I.8Fe2Pq!'~t LuD')gF Ƥ PLpb58 zcc81g $sb8t0VGro#+؉yo ĴGN UBXi*Wn1٢Wg+ ڂH\e<\Z8oD7 IevRm,-mӋr:4QWDkdD";W2NIܔDzgͼ6HQ  Dz (3iom ɍ._ y\{7`YDexc{VX˚2 ۸(D^Hnrߞ}*arhhwcst%GYuu<1r{mKv_f7ytpa <:,!:%w.T`f'7&~*U%scI!ǥ ۱8,S&H䓤lxS/D ^dqъadL=b#ɹDHs^./ Xu,;bsFNM U'+@LVM~c̑ /K|ceۋJ<\bڵüSs_}X`7fhhhhhhP_6MO@Y.h|Q)J[z+Ȟ"0Z淋O78X[Sp܇ٸ{|~P9ҵN?ޚLMǫO f\96JOf1,| $Bݘ{mаMv@D -k ='ѩ.@rE )D1wA8[!(Npڤ'ȩK{[ <񻵠X-?lCGOX/HzB1 +ztʲIL(P.p1A'#Z)\0\ C # m){x]"J*[|ЍO2:I^;qb*|#% =ܣP'v I?P;)*h^7M:DAƖͨ˙T6i$C0Hڜ<x<0TPtPB=GtVV OlaO$1c$wVA/S)=h{"2[ Jn_{1Ԗ8V+/ۄ8s6D|-FBSvW(R'L .Crj6"}bCeO1cĒH [֑V% {m BFJWz>YM/OwK' MplP4r6EgظS 7 -phoK*;=8 μ@1ݖ-?aBVk_6(uW!oΫ"r/J7,rO ul~GmK!^;)񏹵K&^;V 1Gٙvu 6 ͕=X~p- h:73S9l nz^Q%`y2 `6V؝;<qRg *rəUę_'\ B0T'-užfAGNo,R$v˖dŁb wIsRc;:4(/ Rв8ZLj.viurZםQ.IJ@4dx`ؤ`;"D[bt$MJm0J2<7?oJys=;G=xxv%d^bƝ:+g;> w!^ۃ>zk7.? _*5Ǿ}y Z@_ {_5v۔v^?cKv@={B}͹v?/{^oqO*;;nwzr:a뵙#Ul9E9="T0sNqէfa0RA7[p滊]d6’f( kG.O|aXP%/>1Sp+%`Qۻ@ݚ8rn`T &L8-%d;D#Gmiܙ.m kB 19{r)!jFv Lџ7 q.ዒ\2)96 #a0 0ah).wo ) oNF8ҡ[S RJQM*u)ɏ.p*L!:MuM~$f5 @0 9<0UV1?LjF0m% Q$*xu+PY%B!p(wP3|(MZ{fЫ=J888cGUv-ҸSt|yQ =A;gqkoA18̐l$*cm4'Iq[rfq\AmR<  wpϲ=&NFhVy* y34?! :Rڄt+jy3G͇-O`Y?HP38D&$:L>,p51?ual6՞pUiXYI46i @ib{ jHDG!#\sfnh+,8f#0~hŤ`ज{ќM! d9#K1/yxr@{r8:SRJ}ŒZly911fr 5J& 0@2<]9aqq\GP62rFD~q`3HǏeH*;9KSC[:5Ȟ9"r]^6ܭlN`h?acOO&HK G$Lyj~8ZS0:df!P+vQ^*u:"S.JBj'ՅG^mm9cQrXXÔEZ8{pɟDPعѭK bq&FvG\UtJiDnhzt@4Ѹ#jGP&i<'SX3B1LKSC!VHDvg]ʁG*T'@j+*TΗ݋uV5 Ej&U'!Obմ7gcj8ɝdkTl EicʛuY:}]¿C;Ԥ #ざ!ݝ |tNyVz-3VX&;}]٣nQ6+7)!(Wb b~\W- ӍqFs}y m:rV2jK ֈ>πM顴["H*&@vK}!c"dh1VRn, 'tCb&'ch?Vr]=\q6I"D530(Y\q:rFglIj=aԔR`9Kæij{cJ:hʥsܷ(MHd SC-BpXۓvɔlĘQe$Mmi}0e@u%Zv uc}<  Xn,l#Q313$ĕ*Tp|8ml)צWӊHת}"x]mv+Y; '4oy* +1N=$n xlё i[ѷ{gtCǖbZA9uxR%iUdXAgmHV8:cccZv:1)GakhC J^Ƶ0'*xuY&ln6Q)צWӊHת}"x]mv+Y; '4oy* +1N=$n xlёprʞ~7"fNj]иd#JLӯ&9/,`ua-$L6 %Ԑ2^{afmBPIDn0 cR9daG)RA!#QhKHro.R`a}. W>UjV"AGԄ4ls3mP [ʃcr*y:?EP0-êXc f& +gRE m^G~ʶV+t)- qwn@J(:I^[3XĢX.l8Q׾ -s됡1 An$nxq57 L,z]ȃӗwm7dpk cN*į]~uàMVT/f7iʉZ%0A=e\#(׏R~/:rkt<Ӈᅪ VdO=XȰ J")3/쥮l;ŪPim>rHrB)!uߖ Xp# fʽեh3>rLr]!P:\-[ t'oS/jTRE SmmV c6uM 8ra9h~'g&<$.'fGSp̰M3g̣d~PE@ҦNDZz:&FF"y~CBzMvr l&+)m.0p`vTFI?2cH<,aˋdҮ$2q7 dD/qktThIt<3x 4ikgآGr|Rc'9KP %8Ձ6߂Z:fvhqf̭>N8yn>Y!\;cZ[G„ˉ&`~~UvE Z>4LZxozRFz_zh>ONNǞF|/þ<{w7?4%='tVz/J4ВÈnIu GF|J#nj @D0؇e1nw)]]x;л+/%R 0St9NNTq=k G(>Ư0#2xzme,Hf592919>4*Q&q qJIt2侺j< \V3iLp;q @xbǂĠ#La&l"fBbMYG,i}`}iY*jN>^xp×.;«k#@.oʊx6-p(^Ҹp;+JleY%=bǷ6hl&O~NtvGx HTI6bIsQq)3BࡿgVʑgi8ol;d>|cv}ۏ;ߏ;r>׳?Ŷo.L[~^|ro7'˓ܿmǠ>x)Q=qÇ\r{ymq収o=o\o2mymϖ9ɷm\&N[}˗mǗ.;smn|vǞym9q۟ 7m@})Q=qÇ\r{ymq収o=o;be1m&ظ&2{{[oZTăax43 aan v韜;<שM:Tp'M sO~ie~;ߞrߎw~;}M,TfcWX|A x1Ka B2Eogh9}"=X]ۗ .\<Ó&,~_g&>||wۖ/o2ϖL2ed'>_&q}oqm&:|\rpś..9cχ~N[{98m9oɿ=|o>l9~;Ó.[}ߎo}?ɠ?ώL92brc>?.}m}&˗.|s˗>|o˟>[˗.\yr~\o˾@7˖v˗-qxm;~j6Ef症~|=oˏoo>..8r8qۏUgǏ;|x=ǎ|mB^dV>-Os,R;w"c1|e z3,Svɛ$I˰n.J͔ 6|9mFln;s͓^[q}ێܹ}-?ˠ3 ᇏL㷳-ۇ||@7ϟ)f^ ;ߗ{qÿ]hӬ81ab# vs[83Uc-nѹ$lktTh臮lD--F/$%E%ͥ!d/:+QS3eL㗚V9Q>><Ï x][zn9Hs$T;Fn&u|, 3Dt!(M52K}dN? ?6_diÉ:llPˏ?.<|Šb⹠]uHOݱb?\.}qh'رh]R>lXW4ˮ\Z ,G+T-#G~怛iQ $9y`"6J̘Li0YrlD#AŒnsgFکB`Ƚ_>d"<:B.9\~־F.F,b\7UUNR,}\:'~~\OmՅYHz?YX|Vg+~y#z¬e`$u@=XU䎾q ?<=aV~:Ǡ*VG_8ՅYHz?YX|ZjĶXHlb^J"Yz>PR, C.lۏvߗ.[oMV ?ZP֚uGDV#U-TRp*)O\ 0e|9m./=Šk>G8M`zXU5x#ߜZꦰ}c_{@=T| ~qh<-SX>/=Šk>G8M`zXU5x#ߜZꦰ}c_{@=T| ~qh<-SX>/=Šk>G8M`zXU5x#ߜZꦰ}c_{@=T| ~qh<-SX>/=Šk>G8M`zXU5x#ߜZꦰ}c_{@=T| ~qh -V~WM<6Zus@='՟Tnhj?3qV~Pn:ժ_74}Y@怤2&4Pc8_ BxDGΈ{N\X, )P 2{iaÎKg ;:WIO0Ln_2SE"bxeq/P,6ݟ1}j0dJڣ*;]k6W3T5:ttXɑLT1 42>>o ѧ#'=; ʈsiZA8!^!fXu\SW3>R^;Hf`=cV eC@T% .X- @))+HHKцXMƐb8V&i\mzQ|j`M.Ӄb5RyLdrqț-[qN\7\ @"ޞrv'MZ_{ϰ8J% Yw4Ԁcޢl7y;9bHުσ@!E::]N4;q)c $G/^P#9d%ƗL&66˃e3M_źbbE`g C gPo<>L.$t9!2,#kUVΰ CȐ'J]: UZsuh4 ;^*Ko>ӕ(Z rlX֤X x_OGC}2|K?O(^*zO?V7|daE>?t0`yLY sSѥɟZQi}B*<Ɲf m.>\6/xB;Ai,7ťl;{FAkdd+ gmsN5ʑjM8!oa}|s@uGi*qqc^)l/N GI#GRU "3#͘>t"(_3W`Ҽ?uxC  ~v`Wp>퉁Q²:Ku9b17RH9txN59k|hȴ ϏKVSB/y@d<Wc=-igc!u^rdqMm˘Ǝ *^%@Xr4Ê̡B-#K ѱ͊5R!%vOC .,耮Z%9?Ӗ1'.u/Ѽ[QwJafق@O,sn2)ts4}s1?%b4  ?Hu•sű;C_HS%2 n$Duq *Xb* B1KrM93 0޸Wizkpo3lt$1//ؓ<89}qlk"zv.>=4f:b)n|푬 w ] ƛ{U0k>PQ\cv K0  ؞C"֘1}i5K7.o96)^W8S9UR) *k*B s&vf=E/d!ڮ.qAwdqiCͫ"@3XU RD-AIȇ6` ˔J(rjX"5zU7 Iqͤ=<JGcdg~DENjFp}"N"5c|T^P fvQз8(f2cbCf2"Lё,nOۊ1hk6)c}c+݈"ĠV^"dp1gcԨ$f5W$ܜPءѳ>E`+I. L6\ZE]K\[,YMilBBlZ4&³Z7k2.JfJVKCd&PG@Dl @̀̈́Unj-[..[v̀}}EH3Tl&g 1L߹?YX|Vg+~y#z¬e`$u@=XU䎾q ?<=aV~:Ǡ*VG_8ՅYHVh\Xؤql(Z7,;>Uc͐ϑ X>Hכ&>|RƅάtѯL"o?4lL4Oٖu* e)i^ESI鱊g/!E0O$-;;(J c\m ZWFlo,sxCBA"W-EB(iIf(X2l1jMDiPTMuhsis Zu)P0x;)`Yw|6ޝ7u(lnN[̓h$nMJi.nN3X"TB/`N|+X;rԏs]LO@~`.oz TyY]PLN']ILh)pnGVf U"cN]@Y-^?:D}]۠5{/3*tdr)CO<` lӌ2e>iz pM%ͅ5~c" pD VfV8dzŖDT4\.:x 09SY>fp/NK,:ۇ.)) t#،Z̰J;,R$L}RuyЬlhVo>`iEV6QG2U:]+ ^iW F݈pvPG%bYg CtA;z=}PlgUƫ"۟dNiɡ_bYV \`$Ŭ}"jsD)L 6^oF,A$#oB5ؿj#ņÅ$xwdN>bJUmOǖǵ@Jp c2Wf1,ldIdiQߓtMBf0Ӫ'dP"ƭt F,^Aa|1 wSf-i5c乞W%wde# siD* PZ:@4@4@4@4@4@4@V|ǒ_SEG P(Y rDoWLd8ˏo]}z{I Qn/0 !(T_"e83ੵ:XC]`I 1DݻuV&P`7V7'djݚtgtH 'σ?u[u U_ TC9:L 򺍪.`S@3Z\(@`ߘ/B8VN$-5>FIݤ.K97vǠq<5n'|, Sbrυ.@< # gnWWlHmnGpfovB)5 c{s@zZ "kҡ?iBJ<×&>\y7I[F u ojĈGbp;4m"Fa\s,;>7n/%h^\3r]O?V7|Ig~f㯛>Zus@='՟Tnh\vRP}2pצ>b]e"?&`w,J}^zO?V7|Ig~f㯛>Zus@h3$3' ;e.cCC8tvYS`Pۑ8`HſBTex~l4412K@ׇ@\K ;x1ۺXT(RYqdˏ j: "$RH7=:σH'b,^Z {^xs~O?V7|H=*yEM3'?k}1?OCE}ņKSә.4|;7/1pV~Pn:"ҐzUX&@fN~cێJ/ v52\hvoc^92btҬJF>(J7>h<0 5ro|X3z}Zrŷ, vWO)IIL'kƽW"6fݥ)?f̫狎<O/?Br0 @lt1!:*+A)-$͘D\nZus@='՟Tnh ?ҽko7JM鏚 !\m(E7>kN ҆Jrp|dX3e.}"}qſ,V~Pn:ժ_74}Y@zO?V7|Ig~f㯛) kG@ MeLCLJ]sTsPĉL n\7|wm @4@4@4@4@4@4@@2?ړ~vSDU Ƿ;ĽB @Epɀ#*Kt@$Fb5H` U\>>8FΣ*/ᤖ< bH01OMD@qFu%"|},X)&<t4y8xtIp"Ħ׻#k-='wǠ/ GGDQD &"^3e͐-Vp*/k'ffCvfA&0Ӂ{$ YrrD%-T,\zgBEɸV_% gf"}Do<.c΢A3+hh?fޠ$ᨸ8AH2ۑF5`^`r._K<8GwMb(FTJm2 ;Džܲb(x vL u+VW}&+6܌76Qʪѿ'W0̒Cx|d 3˟K\oPZw˖~\u]@T3g@;H/`22R"-im^'w,4$nK˛Qv{GV6W#g%~pwp ğ^ H;+o.)JNv1T{#ڢrj1ģcB/\ ${w0 ( ~xr|?/{ k/xg=.ǣvӯL漿 g"ʥ G2^ziHeNJHZD>%AWt)͑J@9գ5rnGւ_VWU:džn3+vBPa&V 8lX4ͭH⍭z$:]&Jo 9&?Z RКQpH!@&Onم87%pƷ;[~wO;lo?U!uh<w&IU;r 0ğǖ ;4E4Hx'*G+''զr$B;>NNm5h?2Mrl7M(*\%Ooٹ`1n.,Nj%~_~7#EBۻ Y*O"@է38vêz8jd~75+fXP|:(ZI*8=[g)BOD`>C H F)/\BFX-b݅^">n|PvRL:6y)2T;$|Kb,2)N[3cac(whFdō i~~%."Z/r0gxrU#1xy2yS0;GIp_rqzir1!N(uRޣ)zcU G&IJHB$}LbQ(t/oΉf ܁fgQqtƿu;jnL_Dn˽-XңRHé`'Bk+7Z07Ԉ3$͗mom:k7(d<|dTw;:lPfq,|-$JWg< -I4q}њzt ]Pre"*dMPjDӺLeVfveeY366pu`tLԚu}ǟ%HAZFNAڡ-2ђ`u8ReS5fpkC>X'~D[8|[/52zeXP?!Q,"X/)W& {fÖB?ˣa(zMe "aaW9m\2UZ(Z`K!,=^+/v݅ gQ;#aG-O;y-'Z\cE׿؟bGkP&o.5hR{ݰ _k$U)?F\/Ic#QXƒqaOK8ys js{yq&&fƷ`JCrѾj~wɇEܼ7G=Dfc[2{ 0#♱[ H{˨$)e:C}G/7L3*$AY.f>dI>,#頑B>/0"F$1~=>Y3cٖWh0|6ȍʊFΝ痌ԑ<9>#iDG-?@sf\΍}L}v/e,MZ J ʡFZ 0P¾em( A,-S B-z>6X0]9,S1qg(tBC {5'ru߉^Ίn$I :^AiCY{@ͅKHKPbH홊G}iNDBv5i75~S@K0%R>ej[e+xi`(t_!Q1HO·.V_qRh{>g^ܩ7|~hh ~ԋtW4 @4@4@4@4@4@4@@2?ړ~vSDU EWܳː,5AIJ<aK*VXG%dc 5%9aZhۥHY% Ԫ]1dfTD!Q x(P23Ʌ[….|V+> 0H4 LmbJRG³Y,c6F~dQ7,<柟<*+nT 7fF//B˨4G掦'Ȯ$?M.]w_G1h-lXd0mrfB|^UΓ: y? CmR9vX++$Шks$NmO ODl[kh:p Yle /-66_Q  x*FFxbA!Ҳyy&Z8Ņ@@>烹8J) =F%jxDtݳ$T#0b#wͼ}ceFꓓ5Ȫ0b0 <a`A&=:ҝ?i\J͗&N\{99DEȄJ1PZ%67uლiaNS?$ΏK~Sm'ĞvU翕:?ڝ~7;.tXYPh\rj:[5dpqd}ߏF Ѽarɰ =gH74gy`´*KULHe1AࣈDҠI;W RE;{X d&Ψ W+g:ʁ29k6Tc[hC4g^YOrG%:8 VB7J@6͟Z~O9x/;$I#o{~ ij',A~o/,]!} {6!p@W=c*V>; Gz߿7<]7^p=L)Izl0X~?4+GޜkU@yXV·ƭv{PɅz9Yx@~I /jꟼ/6ј J$D6JI =]ڷ'kD;>HNv =VjG=C@3N/<َ|Q`ػz.}h{ T7q/PSz6Jw#zZ V˴ur\8.B(erCۙ' }E3=77:5ر) |tN$ggc4YǸ_1"1( qp!k`ky:/tʳfnD h;gQu=s'#n7q6'92;rBs95+˷ 5i{HxqzJrL2~[14`v򕙕4F~ `aKnroz 10@sS6Dז"FȂiF"d,J;xbT̥|xFLj t^9]}a(PD ɘ_AڈEՇ6ec^qWAԙrU4 S˲W!w[dӳ8v).0egJg=\I2 KYo^V*߂9c'/zX aSb!C,d 3v6mܹr* jsγ CSF@4@4@4@4@4@4@4@@2?ړ~vSDU ?4@4@4@4@4@4@4@4&X,x,4r JffX`&D,V,Dܙ|hJƗ֕U#X6T>\9qhhhhXuMH3[scJ1bScBh(HcDhQb\6>N{ $uR./ cDu\@4@@4@4@4@4@4@4@@2?ړ~vSDU oG҇ y]ڂK4r?`q;)PtS<ߪaVDI|bpZwz@&,\Ӌ)EX𘾱VTbVo)S7ʷ=[ _и V@ri~`Ҕ[D@,{*+`k"b2- EʠɰAegK!(]fc$D:})Cy..$R'Fq ; 4&,YHءiGx\ۘpcDCٻa,UsmЙHns]ՂtഞF`q<};Rp/J_^PvLʼn@m)ik,JYȦ,GgubvXً5F"~\ϋrqPL# R(`䑄d_D$A׊)BՎvm#H(&nv.qR@FA`Br+I딑J!Kg9XPZo4<zI "k}y`x΋YJR.t9+ Ifg1fk" U.6:r`rFVuR}c[)I)#A^09dBסt[H!rH^9*"MȮ-N^y,>[Dw*A/#r9>30&XOeO2bՃ`Z:X5/V7E花t`c)zR>f-_Ê'Wc["E-)O(2kMR'Ln־@PyMB ~kP>''5$i \cj_V .|i:%ZɚkpMTגИÈƴyʫq1V>lzj~ IC:CT!IQd`l5nMw&χ$Jc *B@`hfNJp msSaan6^A4 W ZHVcVt<^!1h&: 0E2Rfn#.oo,4סu1A/o`D(j/vdr:הb %5G6=BrXYوe5EVptΔ 0ZH\mJF=}^+= V;!ٴ  8lsع;g/JJq7 Id'gdLq!"%Q2r5%YwTLXT2eu/ȕTG#m]^*5q; .WnqD åJX0`2/[W4ي0{frmUqfq%Q|9S'Iz"o0 da}ɠbZ>eMx-Dj5L;:\/6gUc!Xy`X՚t9MʊN,Hh12V#l #Ǎq.mQ 3xr(Y ]p37<Εs`HDB}XчH,#aH03Ĵeag:WK 0D.S,c#z @eRq0ֈ(rB+I2eH˻1 &\}_vt$xs)7+S.v8^]1N5L&cqMU3uqzl+O)y9Bzþg;]m)+L~oD-l"<[ |*5^(E7MNt~z?i)TFc/2ߦ2BL 8zɞJmP挸Y(F@O=LnUx`doU^$g$ pK/r7ceo4p`ݙ߹K y6% oU]Lǚ\چ+3JTnNY)ͱ7hDr?w0(us^ZءDs:%ȃ@4@4@4@4@@H\_깠'ހhT|O{q#bǞW$iYHP$ʧ9ۂNy&N#aTUD*-~@GDLI?yq %6O,Kp> {zZۏ %֎W }Ɛ"Ъ1,g Jo*Wd{N>lDQ7gߖʱz׬?HYێyշjz] ~g;wU:*6gn{U2/Nj97r^ai\闾X>H{ d=  ßC@j)N}Qꟶu![Nۅ]Xed\8ñ,F<63[ M7-$e|Qـk\D({_읋&Oli@AtL!)X34AX*$qƇphNX Fd+CvR^V2s~e} IseHe7bnB{d. @ڻL_yLl$억и]׬6G12C e/-W",q6dųJe{>ŶuD`"@KqP<jd^sJ924oЗ)YܪTf _c,ϛ.:>?Ȕh~*b{Ra1IgaX,5ى6TysIN@Oft։8ACC;>,•4rT/ xrˏ9K`kElnB(LXmdbdɒ^O>3`bACby3ga`#_N#qUGUj3!E*P܋vd*gbf'',])08<׈=ML2PKkg1n'T Q$8!o@nA Qc%΀ն(MU4d|g"OQ,sdCb^hk9V;[r,'fFAMolE-έX;L+o~Z INFr.V2Rݖ_VUU&Dp-axbUr)spo3 9Q;'_Rb3Yx Cfm N"\Uv̝ e%(%xg% v՞j.jk 1#X.!00'?hmBVֹb<\ϱr4a3m(%M%'4 lL+Xb[ @`Ed;4 =~Gyw#Ry铼orWC+s9K`kElnB(LXmdbdɒ^O>3`bACby3ga`6Q}0պZQO0 9ӹ<5)xs.޷u3{> /OնSa- *^UgvlRv(q\' +!m|v}D]ŗŌ0ar\Lzõ M4mWX$jz6^, Qo;bF~Ց.K @1Rߛ 50 ?K#j}Ռ"[`̠d4#INYQ{~;hHt[=,NE0-}GlHp)e4 RNTNIV{>_2kiL|"cΎ#gxȢҹL(d۝""-8s|$; ط2&G `WGP9n=I"cܼcf8 v56 j`&QSO "_CǀLbI^RLu >;4W}e At39x^ S: (0N#"gs[f'yY]X_𴿵L*Ct0tń+b{ E E%`@4CF@+6ەO~ڮG:ϰ70mIN.ϳ˿k7ZҶWk;]e"fpF KI3!bezٴ~}C/@9eJSN YJK1ӿ$ZgHs)M!;* `Ėdʨ~NֽkQvKvjO7?#0zXxDÞVvC+ݾ'2PKnMaV/ (z@~'6zVR%lL4׎Ld`RfƝNe};B;, 'r!<iZ|@@#V>G@(將cw Xn~߆מFC7ӿhvzw@N}o;@=];hoѿ t7FC7ӿhvzw@N}o;@=];hoѿ t7FC7ӿhvzw@N}o;@=];hoѿ t7FC7ӿhvzw@N}o;@=];hoѿ t7FC7ӿhvzw@N}o;@=];hoѿ t7FC7ӿhvzw2T !)>sȢ>%#$.'шCC#mZ9#L8}m;;@K- s=ea,Mv"Y C,ONsLVg+DqQ i v'veCE ǓJyNt0yK6Y`, [pTuIA@LBCr.{C{[7$SNf 1o&;xvB-Szg˘EG䁥Pd"bq$5Օz/#C[\AU8`+^PC Wj=\=ň,.ـě; M*PNC<pF<͛(I+RJ7C<щv]$52$qIe&)c8l+ܘZ-jdq]Â$cA2nysD [T0کVQv uZ^lY2Se$Ugό.Pi{}Y47U˚V$u QU…Xc9c}ƙ$S;ϭ& @*nni9%ހhhhhhhhh 'C_٦Yal`4qgT\ =D6&G^]XsB-QQxF^y1b#vrGN\{w/L-'2Уw#.-k p X9yQt];;J\HmX.$o'Lk -?PpJ%.n&`iq( ] *!<4M6Γ$fB'#0%oI$yO∉l '2 ȔH3ć8Qā MoFbmR)@_M $GΠ{zgi}^Xefyod U6|@O<,ԁvCGOLJ^`xMmᡶ~^!5&^R$DaQLRU[ 2E $Vf - 6x||yB NN<[[F@={$7L3`x RTv-2t &ie+H+Ӝؽr-pFG7 XOɌas}R[b-]F-) Q0}!MM|݋~owZ|NE#C3K33aNn)-,%H Sl,>|R#U|x9 :ZҶ.ma$smCcb9+ʓC3ר XL3bR ͉3xd|p(Q;~`먝cAwŷO]CxW9*Cd)fr!W+CKAwSS 02<,}f?oWM>V-_?wj?9|75xYo ݿעI|Z ~_%}Ux^wysok@]tkOe_71H@a:e,sci@<%Of`5lQpȏi8e^=J,~ @, l3iVtB!ct ,?KvDzlVlX/WQNWӳ'xǁ;v&D,nmfV<'`Ue5黝RM]C\+*$DoO!etr2f渉ىH65tҟ%;*G?pT<1(UIcP;zc=cX^# e:Xdq48f@T^M7aX}LQjC hnqYcvIͻ6LZsve;ao\bYF>i'>BǙdhbrraJr=Ex~,^-tպX/Qj"1<²ݲ7zԘ!AVޓ3 uF'V<ʝ@5zNJԹ]2!THa0\@q8?r§35!mG_Pd<*A2G̛ p>[i,]V'3@5F ɳ*?)&x%ŎJQ,EWZ3'^/6䭠gu5Xمֈ+Wt[%,bXIl)2߼F{(vGv|2 1bv"l)6 d ?X#/EZM$H/6g#^^J S77eRt`GTƲ<Um+LbpJHaliE@@g݄Fz B">% kPQά͇y HC|OǔlRi@&Gv]kJFղkr|F27beEy#m?EEM VH.[o4rQ (;~S(7ÕU<x<|,Tb4A®+36^񥭝KFɸ'xr@X:G@pI~S1C#p(mPsO}pƴAݔ^(Ghc|iܞ%1<9oEڽϺ}y :9I%7Jĕ֋CҞ!Q V# zEMEk}~<'=X;n\)]2^ zsµ~ NQ޾d0mt8s%xkM&3zɾ "H:rX.emɃ`(xwםDV²I24KȭQ#f燐Hu2ñ xZfg!sLCp| (|80,Tz?ISrpAËj3T@JЅ}s&ї\aQs>dDdkED5A1{4qpus̳|eN OOj1Ӻ3rVfC&A3ŸtZO$h-x%rei3,FzIs哇`Q :Ӂ2N(Iazj`}) n,g%yťQ+jyB~<pV@<lPOwhG('ou]GZQ :([vWր~}-b}@{3px0Hݑ t%PCQ`1f``a]):ҏ-5N? x0ou]GZQ :ڣV=5V߹NXpLKo; BۀI=33Ad#pt/Q%)cjgvF^ڹsB lͪx8nN #5ӄ%-#f@{paK!4@n4QͧeӪ:pɺ9{4IpEQkC!?U#rU[3EwWK>@oC..II3*lƉ-ʕ:YNl.Y9("iرc * "CH3PFsvvYSR5Ύ`Oy|Qt쯅{yܽp>흝/@^/+}z8>@z oa~W~yaG_+1%eBmLq;U IbqTF$GۄٚSEQ NSlmfr@YIf DC $HXS-Iw׫3/NL\ޥXic# ҕ+o0&怄b}3ptaŁuJ))qL>J4@ىH%͉BUdϏ>wFz w@=姐^?PWxW;/}nʍgZP!a.h2,r)\δx3+J,HRY%=bLjkNn NgS)KɱKCg|f"j$^&9XJzg ϒ 'n_ɞ>Fݝ]矼kSjwp[}B*Xue<Daq|u+9aBB0r[dI+lmHvP-ȣb<ӦK].D3k3`X'KwT,&`ѫSrKUL&g &F G搇TtC1aU4˂x*H#|:x丵zs KWdh Y_4?hbr5aSw1G&hKVJAgWkܱzdYQep>1 {ЩHD焧-@RT+(yV7HE2#%A}÷vEW5E{.e1xHʪM,sBhŞ dJ`ť<Vc>.^?1[q EL.AiQ cG xbr}V/YMu$!;,$Y ȇ@18o?_弮ZCQqXە51t^,Q?:Ii1 &yXxvAv & eleY;)#Sǘ p< z]f,DFp\!~ /n%+IٻԼ7">xF5")O7/28lƅ[.-dm/Y)UBBWq%\>ys@@@~T}$X/Kk?%=X5>K4jdx&F}mrccvͱ*fmd{T+=JBu j9vg(V"^@xRƏѝj?@dzL;"v5Vu@}<_3 ǖՊ-!ƐFsBk%kR+A#2wU#tcvősS:Msǽ @V=ʀ^?ѳȃ|8ײ2 z<N˜\Y_O2"9Vr{99 n3ul4cGLp wjR<1+SԻ#M:"*/-~M`dHiHG\Gj\Bm?/88s=(;Yր׼? soJqJ)oFG4K3૾Rxh\9_P^F[)/ r %مՉc?;\)Zԋ,2B#?"-@rV~ߪro M >Aݤ>Ŀ¯uKa,0 xZF[_V^02Q^-&5-o[QRJ3s/M.g])u,癆(Bs_0̔:4`_~*@$gltSLC [֨@8ue=p:}>zrI 0l_H}H?C0&H$cF5>)̡C&ew0u&],m킋ڀgb fvlw>2M-R (PqmT]S᭕ό A+xnt<*G%[kBD7dsoBo^@oR tÓ팓CIüWVP؛+@c"2;~ JTuB=uN;QL c4݈PsTK`hɐPaΜ*()k×&LߖmTsQrW!ί_D$Eb(ڔCB*9 6r*\!p2}pɅ+- 0.V qx.ڻZ&Eۜ1(0RSeƫ#FXdBNˆE^0$Qs⤸*Ṣ"%$pcU|q\cħ+KbdmpǛ}|mNuQT+I\fcJ=`d4A]h HUvsgE#Fny]% kZk>*l+q ĥ2㌢'3⼄I%nh]ju &CB}WZ+- m9~OV[[ 16Kd>>z>9fiR@tزOɭJ'4}HncmP9`B?db?;03]Ǝ ' _V%qT}|n;'<9'鎁G޿@<9'鎁G޿@<9'鎁G޿@<9'鎁G޿@<9'鎁G޿@<9'鎁G޿@<9'鎁G޿@<9'鎁G޿@<9'鎁G޿@<9'鎁G޿@F}n ;!Y)Nc4۶|` ʣ}om8ۏu'FGޗ@;êOҍ;؏.wTwz]?J4b>R~h}t:(?xuIQg{@#K'FGޗ@;êOҍ;؏.wTwz]?J4b>R~h}t:(?xuIQg{@#K'FGޗ@;êOҍ;؏.wTwz]?J4b>R~h}t:(?xuIQg{@#K'FGޗ@;êOҍ;؏.wTwz],bWPP!++@Q*X @g\i~8XMG<n{]hh{ZXhݤCL 8)-Kasѥsh`\>7kZ8p&,gFԛUq5C*0O1D`Zc( <\칧:Ys4:qG"Y%>I̔T>3)j8#TJHDF5˱rnQ2m X"}2kKIr;XYzmIeUѩNI4KQ9H$!6JX[wX09a ;).r[(DT` q`j@X܄[h6k!` qlN2vVnY z Ӏ>ɧ4A\S%cXvQK&=qE/K4jFȓ!hƎ]vZra(DHͭQ2$L(u ?+m:ze5%>֫W!>?qxPt՜4k4pʼn}'rRKri0)i5 >V]ɚJ:yqlF:ȃOz1s[X1b 9-wF:ǶS8@uE1fO.c5FKvua;~^V"=nx[qy*k;2g' R5D#I;5QdJ6TJܜ0W QoƎЉH@m\Xcmm (mh sWh,C{nKkǍ)Y 6=3֤V8 مH|-qaCunŒNXU"ULPN\7. m_de<3@ϟgKT"Lb|DSy' O%*iok\fY#7p*Nx0W!ہjt2uF1_k q*843xq?(#QƑ\++[‘o4[7-Ι xc⋚ Bo{4~k9q1䒈R 0mÒR8}xXEyM"&pE" )q9u!XY]m$M!QU:y1w8A35 ^R5aߟ,97 ~(Id\C$+#l G=1b԰#fy`V*pRХޙJ |DMʹY>Qx2ِ/{81xюUE/4J8D>o+dȜsfI2EK.>jAa8Ҋќ 92m*koi?Kllqd8/S"?`ݴBL ZQ(͓ŧ/TA!hPrl\\u9q`p!*B1|kf M@A6(Qe! QP&.̷M\hh W+:ޯ~9=k[~_^{ϗ|/'_]2dy}xx<7ʯ󛻿%=kݚ윥ndղvnrޝ.0TU`"bØC"̧QQ-[xA,4D*T yVU9håDR/݊-EjJWVl #Ak!⠌2&]2N/wώp#>0C=XݥPC< ٻ{+adO #Sx4^Q^FrCϛ %q|mR;_W{i<;ƐcjU}?Q1kŊc&v%Čqӛ!Q rg)&R4=ٺMi2y @Lj #Ρi#f&K/gF`?oN\rO-BDؓ47*171ff=Ұ7)Iꝥr0]o ~fS5Fda%aiS#G\BڛD`*T1J yH 4 Yby I8ֻ4g0FOAyo[ M\Y,CacSg7, W;boJ=HI-UnuqD9y)drYΩեݳ^b͜ d! ) _ޒeHL4N%`f@gg(#L䌉8 O2jh,.Dd4K55h+\\⻻PX@V Cѻkd BZN9$fʙ24L.{%&[&yb XNzXlA˹6]YM3A;k3M5-㻘_ `stfk L&y`Ё]1j0fKK@,]ji~jV EOf V $ U(]H)/S+aI@q&g)c9;PՏm8/ě<3=Pn1?u;b~ IyS-;HFلRD!ɩ6>!VйJeK7ze.\k7 IS+Wt l!,FWb p M} &$lĘÓݶu2S 0LJ]x52[$| 1i0DԼUK+[^YMxt#ٙ/#lǓg7)=$oC <--ڶ+.ő&IۙwB&Bp U,X#s6GE*G#l„ J_뎀 XNX̒sJX+UL:Y$ T J֬m빸&ߚ~)ol|-0q

?,#G09LW%H_UHsaV7'ЯŶp-۟F}N?=e]q HO<ڧRe,6&-7]OwiI)NYw!am" V ŷ&Ru AIZ<Ȣ #eg (Uq&jh3Dm;ÒaMzr@y?e{݀{61FDȣ4goVmc)֛j[$ڎ578?9IJ"S( 88:(T(fdx8j=Lb-dLVXPj5.0ne]'ċeq7'*YY0'ѱ:=ZQʝO V/K4l oL4A9y\G2 I28,!c  6B%] Fhw湃Pӹ !Q^2=A<*\Iȝϋx @^&R}~ ]+{wzy=ܠ;۲{]PY<ǂ'Xcr98 R6'v DŬ*tXJ#ܷ.uIl^0sPEn|w3\:ԉ%tC䮿D+W2uzo[+i{FgY՞Di Po!׉,T()mNq:n.̲#ao#A#o+Lr\@gp&I;ʀ)D"ő$@AMA4L c4XB'jJ!G'gnE[շkNdjչBl Mⲩʑ1nD:$ꥸ̲$cѥw:ftzOu.]9:ԯ4iݛLR9Hj19p={n@Kn/HԹu',}ߤ[a2Nc~0~ aSG;5:-8[ $j`dl4bMj!d,NcSؒ (J2iw!,/HgeEAk]:po6Lsg ^ sp)=a4Txpj- mSH-u"a"uF^Q-f&kn36g753U(}R|0:$`/olɜ![c(fL$!;x˻V4Fd>7 aw@B8BȱB7V^~jMK3{N9[.oRk dRMeYC$M"@ &GCE.8?J{ nq$!CU7͕8FhVUl\$xϬ3U|~z&h@Vd)H,ޙxU5⠙w1\7 J][mOrihkN(!*51p*?`e谁dZޕN.9J{ݝPQks)e֎Y$H%,\ c42./Ts<ԥ)[ҍٜuyY@VV/ڗc?P*?z ) D&SSK݄X6A2FЊcI!& 3a8HtqK@hx1=L5!~u꥗lu.[)bQibu~uKBA#լЅe:6EI!Z[M7 heFkT`1ha&jcj{B4\Xpzc`֥Vkv1-CE^4!VQT]܌1G&M+ϙ9΃b#k~A 1lai"-R+/dbj13tau9)X.a*\R d@Ϭ_ԉhP+di ҵ˽2MsksK_rF&韼X:ifXnM<{䄕Np+^|iL ¶Cmn-~[<@mGRF8mتąP!Ha:vJ',W'D^uJ?eW?B/(?zw%]{5A 'pdlRLn178$0ob>~+& 2N@*ҭ\pedup(s]"aDt6 .c|Ȗ&sYMK/pkWn9;zݖHkP# 30Y[w5tD2 nWFJe&8` ,.P% `t^XGk +e3XPq/iS6~#H43)湩~z4w2h3#OJdn2Mz-eGC* ^cO?$Z@ RNS^c*#~+Re. :RHO8WbA13icڅƯ|t΁cҷ uZByN[d-~kN zP3oOH?Gs~D||I,\iߴKs[ XFv4qh~Ֆ8WY:0*J[⽑u3kjD+@$iѽ(gTkV巺 N(XGt'VC^˒5we+q62`"0E&TEs,u~#5Dծ[-{n=fx'=6pWFI|M:d@W;?GBDo\E۳h%'dDth@4@4@4@4@4@4@`_q19@՞Dȴ¯Q'q\bRĨz76T yBZ\9 ӮR~#/%5j93 qdQVEMdO C$fnj}PVv\x'2 RK*|H.\Z );&G69|o9Fi Pt+S䇵*`=siNT>ćǏ+`Dsbf#s\jA k!B] c插ֵG;Ƀs@45]#Ջ\sxZY KPc=I˶:rN΃*L6*5ҋnw+}([ɦȞ>kkJ ׋)Oʗwsoc'B큟sߗӥw|Cy#İ\0z"H?3;ou[/r&3{wuM <>ŐF6McvҖf&&;ES\ǰQ`"|Lҟ+mþl@68a !%!0dj- 2 H P.Npt:7ᓗ=d]a? wg70 hv^.8Y+a5L-h&z}_.~TD @WNxr@e*\1{}$Cx cxTq`OHA"jl,ةPfq1"ɄobS@G1FțI[xs a$C+@1‡}&*$Qoq1$޼I)Zrأ4nRJ|>j!jXVTKXd2 Y??i'O"8r<'+[c`@C8)+X6ŊZYQ`jDpiev#T};`aj{ڝV H) |Zҡ͛ߥġ=㪡I-AFRiX-PT=it,be3b~&MgȒ8=C>(˙@!fYI+qVFe\.,Vpgf@ljElSsNj60$K\(Xr?koSx}:fpыwCRƠGY!Ԫ@Vާ2!HeO>P!yJx e픇9JNqܞzq8yL|1$k::)drj rU?2 Գ|NJ/8ILe1MyL]d8He[3KhpB|Ĺk%є&kMw%4a,uj G,'d}pR z o `JL ) CP{Hf{ը#Tޭ=$kl>VƶZ隱rF)Χ? rZP=KJY=!ߧ5>7d)9b"ĉcd'2l|f)ēn:f`K(` YK[7I4n,aWs'?_'xr6k`X̭th8 +P+ m9 iA};C2NP+d/3@#ı]do#)ӰSI@A&9cyDb}k3HߏMih@O+Y7rRF -0g%?0C<,`F0hNvZVdQ$6nuqkr$8x Y/O<\ ۝ڲo k͉,Qf,uDlVv6o'P!a`AZ9VݘQ ZyALQ~K2Ỳ{ނ%ǫ_n$.xIzWe{ݾ[wGtv_O6& R6ak빽hZ%%KEA y[iaZ%V"LNx8f\=,pbcUIoTNq#Ҽ"2E ^V"elh`oP3Ss{v$Ȱ O;I/B%_*{w^_GW?%w&Ue%Fr$EbzToݹu* /;4 +8P*pU 6 H^6rB<{ P0V#H߅IJU4=vNzsOH_D~3Mb9nF_gg7.` ،z_\CY;cup,Sɡ4k^Z,)U 呂m4b!;0wm;b0%]RfOQJg@Zhh@4@4@4@4@4@4@`_q1CsfR]H9 IMYENB%'6/aؖrRٲE"pG:s#FLUd Y䔢G͐s_6pfbfSB[4V?.pF6ePeU~Q=ب}VyZĆi"[̶maQ§UC9Җcl慡+kV@g6DOT$>:O3-°|zG"&`4Y8:Գ#,\8biN)u n2ڛ}+u -zl4JVhz(?X.s`F7TrH8Na/KU$ڋoGω+? 4ֽGE\ < )Pya{ɓ<߄=țUbtܑԈu$Kx`sx0Ӊ@aܙ׶8o%x)vB3t«bȥg'9xa/ vź™oDw_:ؗEQ84-0afAnfWPf MO5LQrƝ&Rc}ξޏUI9{,#WKr)]?ld@+JST+Q}n<\G/ TOr;fn!B"9}y6 MK {f]bvOd?5HqK9 ~sʯ-?~ۗwn.6S}_<ˇmoM~++K=Ct KO/[ ] @4@4@4@4@4@4@c^(%]C,]vPv=cpOvX3 İE]".cuy'6pf6^Hm:D[,D&}ŋp`6g:1?]:1?]:1?]:1?]:1?]:1?] 2{]1d}sZ;LJ";-'$8Xc[(sp|g@v#_@v#_0Z !7L/(H 4Lb ojhY7!?q-cvߴ4w o\y8 !Ѵ/^4Ckjg6nb::ҝ?iZJ͗&N\}Ω?Ltb>Ω?Ltb>@=Hؓ{&j<đ 9Ιnr_W.j2a*}cˎNY@ڞV7j?f+z5Q}MپtަMTG`~oS#o?z]򷩿U7.y[骈ޗ@d̛la8|yqv @4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@@4@4@4@4@4@4@4@4kMݾJW?U>$/4BAb$ R:b𥲒#ȉc #YRK xmlr幾g2ۑ$nj:ZݲEbiMT{ߖu V:F*VTjr5Qs+Ӫc:+ЍLvhTPmg A wFDYF:NAj9k40$oG=╘',`,3F}^9Sn}jM[QםJۦe] Jȍn$&fnʷJ=";N&Ve:3gyVP1)eb '$';Yϛ[XjsK2gnIsrukpqop+Ó~.=yOy+dN-ZV'b i7Mm{1U۵?ny^\Ļh/:ީ]nb1\"5p}OuCI;P%>`wd`bC.u<(k܅ oypqriYg^|ԼPuwKcbXv8 6$tL[iYB[tQC2ZB(B:`#lwĻښc۞|5?vڎkFڍf9eV/Y{hܣQ}_r'ګW5eU:'"΋7U5&?f&PCJg1l1`:Cmߛ!Vql6/&m2fz UdrjpMZثfh },C< bHjƮ{nYS&TSsZ5ETEEE.0MMf:U?Qhݔڼ6e@Fs106d)&[*Art4Ec$5UۼKϿys=%s`ds#tիQk+svRֆǪH.WꩄL~ 4gqT'H~ɞ["]gfJ3 \ qL1j\cpu*+R\gYxc7m9G-_¥(*N`^JKn[TԨZVKk"/Lzy*W$CFqĥL0ܕ!;o%Gm͙JLMokqw^k==s~Uh$s֤2ɪw3 {f8չZJjgۅOTN3TEE vIV__-HH.(gw;Ǣ'{9[{Zo3y z+ }*\x75=V_jmۍ,Y,e|_;ƲbfEfdƪ$xvV]N{**ș\.:z*[lWP ,H+Pk{pi\u55ðq!sqg e\ͫr:ڟ_0|߃pmthY]Ͱ'GnU}8eA rz@oVfUllʋ*uk].Q*^dQ%ᨲBn2Wҗp;be]T7iy.{2:ɝ{^ s&|In֭= 7f& M߻K K)ro/C+}:iݒhmw*x/jDx2؂H>6јJ:j^S3}9C𳂎x1v);?o85UfǸ|5Ws=^`{,ov"46vtYkDLez𣰋W_qI=V~R )/B1Ch#qJNYߣN[C)V۰,vyOl6eNH^kiH95h٫J][7*1JeUDUEF"=SFS~n^ DY>#yl(K6 )lO^"rm#j ѠabvmF~hrηvMiQvYF~rZgʓ2İ,=FHlnc܋r49W9"b"(TEO\} 3@ 8@߈g!yj#N#&a MeK7Nٝ:|R>\q߈oۧ=ꔫ̎h,69Tk-y%^]1WE">)1m3Gb&M*S¢.ӪuNMזւ2e 0$E 2<Onm^[ tS7cGdzż$79+߱_Njpҗt߷5ڥac, uUyM41v{$1Ѝ'FD+Z",tV3~\BYE=V~r<C9K3$ϰ0-`8@c eJDH^ͷSsso5rqi,vZ4ḿfI<^9jLUe{(G>DUnpLgG"uV)ꅅT@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4>=1;+sJu_cWP9fvc΃ ͉;R$!Aruy :s`xF $~lea=\QoIw6v*r::&O%Ai'n+t$J1:H6VŹ˗&5U2rO+ZUY#t& %~ڵ:VZ"lDM$0sY%Pf|Ѱ{uplRG(۸Tmj9Y]$VFBR%[vK-Y->H6y!DDތUG9UÜw+px6#51:W}@@A(jV4mAL#I&H儤;&&H.;1aDʧk;3|g>,ky7},]{~T z+׊Њ5FZś I>;"ۭllk[csUQ\UUʽZl3Epup}~ Oڴ=oZO^'Im!Pr驂/%KY r͛;. PQ7 {9'Z;굽hw?ofO5K[]K}KX,3XZzʊzp4CЦgǪ5}~]K,L1-'8vIaW>HaE$kNGXn/ǷM;[M&" ۧczvgnfabW3&ed Yیv+$mX JF#NG\:DgtNs<"ϖM ,ޝ%Pő#~bra]WzB=j K\w!T hjdG%:hƸϴ~=nzuKNH㒅OيrC s6>+]#᪌S9ďBn4Lz$ki̙M~R2c8 Wdip?3)A$3x $,9֩ʝe0|B^>ݿa^}Z<e]-aJX-teJ*گJ[vmIu>"Dsrr+Z:dlW;W5 ^s:tU5uaCgf8\0\؝**|OߤۛW'W6yZ`ϲLv_20Y㨷~K9}s ԓq%y'6VŹ˗&5U2rO wlV+^H*g+kL=eΎ_U ;%%k{d,x/UkW|qfW*TSo&koSm[;[w"mkvn+%hL{GeQnԌWVkҨMϡ8ⳣ +{p}ims4Z_|U; w ;5&oH:}L\jYvVv {$dKnzE=&q9Yc3Q2$%jތS(ƦQL'E |mXl{-#𩜯-07:8K}T*\씗B(BaĿXtVW _\p7gV¢oy7 [rjܢۿ/v k[> Kv'Y^8+D́ױvUkH~j*Zϊ.T[b50, e+mF Ԥe1"0ı1 1V᝻>[4N߹*J]Ó=}2;w8,rʶ*+&;Rv6UkF[oDҽ>L'B䮂`X6$J) ~3tb#m١ѫY4[M:l[,$$RFį[;d 8+**TYꯣ:-={A@6Vʥ[^#3IF1H$I7N<4R4I[-ӣNd-yվ^n-FŹo%5xwUgZWkUh]9 {vFǣ«3MWsgJ:t({Fb(zңW)gečވ.M`EK5hy>pMhFrlߪfncEFcPuZt,AӶm]H6_^&ڦc!%K#X$uQQS;/gF.^Uôaª&W } ? {f2||  ہ uqHglSKRLX fإj&4I֩?7.n&Rjnhj=l߰-9jms\adlIfI&zv rjGJj+d50ܣ1DDD*Ad&Z+g*HZIyD"[w8LV~?V;%pNYNu^8xcƧӵ}d\{7+86}fV'@;U6ZXTY9yۖGL=ވ(Ά*ʛle$領S` cb1ȼ];- ٕnCgEh] ~FUhs`H>w(22ީ:6'M[mQؚz-gu8bjl{6cW+$BP]N˛j9]z"9W.s­EA/͔baxCu5}za?fIyl'6f~Y*8݁dM0gFiQfh7)+ﭼM3IkOׯ^FWWwnjoU~^;--(6ujG't|BJ.V`QKgJ&oj4A4vD3epq#,c3:JӕgK1ou͹EQmzl:voFߺߙՠGj9d!nU%rٯv>9^⫤s^Ʀ\U2U:[%w~폏-X==[V[\o[Lꭋ7"Lnmmnѱhw ќwۿV+w {죪:oq,$Hi,fI's=W'6N?pB`^d:ӛL)prrՍ˶*ǭ%(J8ձ$0aSDsrW*EJ3t_:tlV\Mvo|_J6٧u)Ry=ґ1 >$+wjUNڣp^X\ҢW$]?Os;} xmʻ aQԙbh"z ˓ߧn|zxoI S<ݱڼ2>ܫmR䛕{4lO4llD|wwLܻb{_-j6jUہ{s:Ek2֢7UTN1ȴ $ 27fon+|?Kgߓ(qY2$n=.X}oo;ݛj;D֥|Az#1[u莓N"*'^l"5W:&W>w @4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@4@B$$Ifl }  #'*HH8 t0+6,,,,44 laB$$Ifl }  #'*HH8 t0+6,,,,44 laB$$Ifl }  #'*HH8 t0+6,,,,44 laB$$Ifl }  #'*HH8 t0+6,,,,44 laDyK )http://www.nephron.com/mdrd/default.htmlyK Rhttp://www.nephron.com/mdrd/default.html i<@< NormalCJ^J_HaJ@mH sH tH LL Heading 1$ : @&56OJQJ\]aJ<@< Heading 2$@&5CJOJQJJJ Heading 3$<@&5CJOJQJ\aJD@D Heading 4$@&5B*CJOJQJph<A@< Default Paragraph Font@B@ Body Text  : 6OJQJ]aJXCX Body Text Indent ^5CJOJPJQJ^JaJ4>@4 Title$a$5CJ(OJQJ:J@": Subtitle$a$5CJOJQJNR@2N Body Text Indent 2 ^ B*CJph.U@A. Hyperlink >*B*ph,@R, Header  !, b, Footer  !&)@q& Page NumberZ\Z z-Top of Form$&dPa$<CJOJQJaJ`]`z-Bottom of Form$$dNa$<CJOJQJaJ@@  Balloon TextCJOJQJ^JaJ:'@: Comment ReferenceCJaJ44  Comment TextCJaJ88 Comment Subject5\t zzzzzzzz z z z z zJ+#L.2~<KE OYcPkt) fLo 6  # /Cx>j$ D/MI % [ \ s t  < w x  g [\g671Ii #gh{| %}~ /WvTgJq\]^v)*+ !6!t!!!!!"="l"""""#*#+###6$b$$%%%K&&&&&&&&'({)++!,,,#-a-K.L.// 0)0*0000011u1v111111'2L2n2222223343d3333333 44X4o4s44444445,5-54595>5H5M5b5n5s5y555555555555 666$606>6C6J6R6j6s6|6}66666666666777=8>899D9E9}999$:l::;;;;;~< =8=9=A=>>>>>>>>?????@@ @@@@@FAAA'BNBBBBCDD2F3FGGIIJ8K9KKKKKK;Lbbbb'e(e`eaeeef'fEf]ffffff gHg~gggggghh3hChZhmhnhxhhhii9iOkPkskkkBlllll-pppq\qqrr;rrsisjssssstt00000000000000000000000000000000000/0000000000000080800t  0t  0 t  0 t  0 t  0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t  0t  0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t  0t  0t  0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t  0{)t  0{)t  0{)t  0{)t  0{)t  0{)t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t  01t  01t  01t 0t 0t 0t  0t  0t  0t  0t  0t  0t  0t  0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t  0t  0t  0t  0t  0t  0t  0t 000000000000000000000000000000000000000000 0 0 0000000000000 0 0 0 0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000@00@0 OOOOOR  '8Afz?CDIOU /$*579:9AF!Q\Wd'loyz@BEFGHJKLMNPQRSTVWXzA0BDm,Mu6GJy###/0 09KqKKtXXXXXXXXXXCX9@CR!8@0(  B S  ?1Bn,IIIIIIIIh2h3hBhChYhZhlhssssssssssssssstt1Cn.% 1 5 [ < G O Z[gu~#N[gGJ{ssssssssssssssstt::::::::x !t!!!&'+!,0111112334445H5n5555 67YYYYjsssssssssssssssttJessica Kelley8C:\JesiWork\18817\combinededitspharmfacilitatornotes.docSPunitPJ:\SPUnit\POGOe\A Miami- New POGOe\Renamed downloads\18817\Facilitator Notes.doc R MRŽ!dBR(l228+D4|"n$6" (d#+odn+v5=1AjFnhAd)AzehF p>tIjNVd Uq^̎^t$N/aNR_SbMjg8Uy=n8r"89otAYq&Ȕ{irzezzd U hh^h`OJQJo(h88^8`OJQJo(hHh ^`hH.h  L ^ `LhH.h   ^ `hH.h xx^x`hH.h HLH^H`LhH.h ^`hH.h ^`hH.h L^`LhH.h^`.h^`.hpLp^p`L.h@ @ ^@ `.h^`.hL^`L.h^`.h^`.hPLP^P`L.^`o(.^`CJOJQJaJo(hH% pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh 88^8`OJQJo(h ^`OJQJo(oh   ^ `OJQJo(h   ^ `OJQJo(h xx^x`OJQJo(oh HH^H`OJQJo(h ^`OJQJo(h ^`OJQJo(oh ^`OJQJo(h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHhpp^p`OJQJo(hHh@ @ ^@ `OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHhPP^P`OJQJo(hHh  ^ `OJQJ^Jo(hHoh^`OJQJo(hHhhh^h`OJQJo(hHh 88^8`hH.h L^`LhH.h   ^ `hH.h   ^ `hH.h xLx^x`LhH.h HH^H`hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h pLp^p`LhH.h @ @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PLP^P`LhH.hhh^h`OJQJo(hHh 88^8`hH.h L^`LhH.h   ^ `hH.h   ^ `hH.h xLx^x`LhH.h HH^H`hH.h ^`hH.h L^`LhH.8^`OJQJo(hH8^`OJQJ^Jo(hHo888^8`OJQJo(hH8^`OJQJo(hH8  ^ `OJQJ^Jo(hHo8  ^ `OJQJo(hH8xx^x`OJQJo(hH8HH^H`OJQJ^Jo(hHo8^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hH8hh^h`OJQJ^Jo(hHo8hh^h`OJQJ^Jo(hHo888^8`OJQJo(hH8^`OJQJo(hH8  ^ `OJQJ^Jo(hHo8  ^ `OJQJo(hH8xx^x`OJQJo(hH8HH^H`OJQJ^Jo(hHo8^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hH8hh^h`OJQJ^Jo(hHo8hh^h`OJQJ^Jo(hHo888^8`OJQJo(hH8^`OJQJo(hH8  ^ `OJQJ^Jo(hHo8  ^ `OJQJo(hH8xx^x`OJQJo(hH8HH^H`OJQJ^Jo(hHo8^`OJQJo(hH8^`OJQJo(hH8hh^h`OJQJ^Jo(hHo888^8`OJQJo(hH8^`OJQJo(hH8  ^ `OJQJ^Jo(hHo8  ^ `OJQJo(hH8xx^x`OJQJo(hH8HH^H`OJQJ^Jo(hHo8^`OJQJo(hHhhh^h`OJQJo(hHh 88^8`hH.h L^`LhH.h   ^ `hH.h   ^ `hH.h xLx^x`LhH.h HH^H`hH.h ^`hH.h L^`LhH.h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHhhh^h`OJQJo(hHh 88^8`hH.h L^`LhH.h   ^ `hH.h   ^ `hH.h xLx^x`LhH.h HH^H`hH.h ^`hH.h L^`LhH.hpp^p`OJQJo(hHh@ @ ^@ `OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHhPP^P`OJQJo(hHh  ^ `OJQJ^Jo(hHoh^`OJQJo(hHh ^`hH.h^`OJQJo(hHh pLp^p`LhH.h @ @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PLP^P`LhH.hhh^h`OJQJo(hHh88^8`OJQJ^Jo(hHoh^`OJQJo(hHh  ^ `OJQJo(hHh  ^ `OJQJ^Jo(hHohxx^x`OJQJo(hHhHH^H`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHII^I`o(. 88^8`hH. L^`LhH.   ^ `hH.   ^ `hH. xLx^x`LhH. HH^H`hH. ^`hH. L^`LhH.8hh^h`OJQJ^Jo(hHo8hh^h`OJQJ^Jo(hHo888^8`OJQJo(hH8^`OJQJo(hH8  ^ `OJQJ^Jo(hHo8  ^ `OJQJo(hH8xx^x`OJQJo(hH8HH^H`OJQJ^Jo(hHo8^`OJQJo(hH8^`OJQJo(hH8hh^h`OJQJ^Jo(hHo888^8`OJQJo(hH8^`OJQJo(hH8  ^ `OJQJ^Jo(hHo8  ^ `OJQJo(hH8xx^x`OJQJo(hH8HH^H`OJQJ^Jo(hHo8^`OJQJo(hH!d+^89o"l26"_SbjgR MnhA2p>tIA{irzzJNV1AJhFUy=n5=/ad#+q^n+AYq          (;                                                                                                                                                                         Jf                 33 44X4s444445,5-54595H5n5s5y555555555566$6>6J6j6s6|6}6666666666677t@ B(TVt@@@X@@UnknownGz Times New Roman5Symbol3& z Arial3z Times5& zaTahomaK@Palatino Linotype?5 z Courier New;Wingdings"1hFĹ&FĹ&Rl&i_ 0Eqb 2$x0d+usB 2qHXSmall Group Session VHASFCJOHNSC3SPunitOh+'0 $ @ L X dpxSmall Group SessionmalVHASFCJOHNSC3ssHASHASNormalOSPunitO2unMicrosoft Word 9.0@F#@I2i@A@A i_՜.+,D՜.+,D hp  SFVAMC0+u Small Group Session Title` 8@ _PID_HLINKSAHZI!)http://www.nephron.com/mdrd/default.htmlMhttp://www.drugstore.com/CW!http://www.medicareadvocacy.org/I]http://www.medicare.gov/.4'http://medcalc3000.com/GRFEstimate.htm@http://www.efactsweb.com/{/ http://www.pillbot.com/*6 http://www.costco.com/Zhttp://www.walgreens.com/9+http://www.familymeds.com/Mhttp://www.drugstore.com/~e 4PartDChart2006  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXY[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklnopqrstvwxyz{|Root Entry F@~Data Z+1Table'^WordDocument%SummaryInformation(mDocumentSummaryInformation8uCompObjjObjectPool@~@~  FMicrosoft Word Document MSWordDocWord.Document.89q